Wayne State University
Wayne State University Dissertations

1-1-2010

Towards An Understanding Of The Etiology Of
Abdominal Aortic Aneurysms: Identification Of
Genes Implicated In Aaa Risk And Development
John Hunt Lillvis
Wayne State University

Follow this and additional works at: http://digitalcommons.wayne.edu/oa_dissertations
Part of the Genetics Commons, and the Molecular Biology Commons
Recommended Citation
Lillvis, John Hunt, "Towards An Understanding Of The Etiology Of Abdominal Aortic Aneurysms: Identification Of Genes
Implicated In Aaa Risk And Development" (2010). Wayne State University Dissertations. Paper 102.

This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in
Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState.

TOWARDS AN UNDERSTANDING OF THE ETIOLOGY
OF ABDOMINAL AORTIC ANEURYSMS:
IDENTIFICATION OF GENES IMPLICATED IN AAA RISK AND DEVELOPMENT
by
JOHN H. LILLVIS
DISSERTATION
Submitted to the Graduate School
of Wayne State University,
Detroit, Michigan
in partial fulfillment of the requirements
for the degree of
DOCTOR OF PHILOSOPHY
2010
MAJOR: MOLECULAR BIOLOGY & GENETICS
Approved by
_______________________________________
Advisor
Date
_______________________________________
_______________________________________
_______________________________________
_______________________________________
_______________________________________

© COPYRIGHT BY
JOHN LILLVIS
2010
All Rights Reserved

Dedication
To my wife Denise, my parents, David and Meredith, my brother Matthew, and all of the
other family and friends who have given me support and encouragement throughout my life.

ii

Acknowledgments
This project was funded by predoctoral fellowship AG030900, awarded to John Lillvis by
the National Institute on Aging of the National Institutes of Health. Additional financial support
was provided by the Center for Molecular Medicine and Genetics and MD-PhD program at the
Wayne State University School of Medicine. Statistical analyses were in part obtained using the
software package S.A.G.E., which is supported by a U.S. Public Health Service Resource Grant
(1 P41 RR03655) from the National Center for Research Resources.
I would like to thank the patients who participated in this study by providing research
samples; Katrina Goddard, Rob Igo, and Qing “Jerry” Lu for their assistance in the statistical
analysis of the genetic association data; Laura Cox for contributing baboon aortic tissue for the
microarray analyses; Guy Lenk, Magdalena Skunca and Kimberly Powell for their help in the
isolation of RNA from the baboon tissue; Ramsi Haddad for providing use of the Nanodrop and
BioAnalyzer; Susan Land and Dan Lott (Applied Genomics Technology Center at Wayne State
University) for their work on the microarrays, DNA sequencing, and SNP genotyping; Richard
Vander Heide and Leigh Hlavaty for their help in providing control aortic tissue samples; Zoran
Gatalica for his help interpreting the immunohistochemistry experiments; Charles Schworer for
his help with the formalin-fixed paraffin embedded immunohistochemistry and Robert Erdman
for his work on immunohistochemistry, immunofluorescence and cell culture experiments;
Jianbin Shen and the Li Li laboratory for their help with the frozen immunohistochemistry. I
would like to thank all of the graduate students I have worked with in the laboratory, Amy Boddy,
Jennifer Nischan, Thilakam Murali, Shantel Weinsheimer, Shannon Wills and especially Guy
Lenk for his help and inspiration. I would like to thank Ambika Mathur for her work on behalf of
myself and the other students in the MD-PhD program. I would like to thank my committee
members Li Li, Gilbert Upchurch, and Richard Vander Heide for the advice and time contributed
towards my project. I would like to thank Wayne Lancaster for volunteering to take over

iii

advisorship for my project. Finally, I would like to thank Helena Kuivaniemi and Gerard Tromp
for their constant support, advice and encouragement during my PhD training, even from afar.

iv

TABLE OF CONTENTS
Dedication................................................................................................................................... ii
Acknowledgments...................................................................................................................... iii
List of Tables ............................................................................................................................viii
List of Figures ............................................................................................................................ ix
CHAPTER 1 – INTRODUCTION ................................................................................................1
1.1 Specific Aims.............................................................................................................7
CHAPTER 2 – BACKGROUND AND SIGNIFICANCE...............................................................8
2.1 Pathology and Natural History of Abdominal Aortic Aneurysms .................................9
2.2 Epidemiology and Risk Factors of Abdominal Aortic Aneurysms ............................. 10
2.3 The Genetics of Abdominal Aortic Aneurysms......................................................... 12
2.4 Clinical Diagnosis and Management........................................................................ 14
2.5 Genetic Studies for Identifying Complex Disease Loci ............................................. 17
2.5.1 Linkage Analyses of AAA ..........................................................................21
2.5.2 Genetic Association Studies of AAA..........................................................22
2.6 Mechanisms of AAA Formation ............................................................................... 24
2.6.1 The Immune System in AAA .....................................................................24
2.6.2 Expression Profiling of AAA Tissue ...........................................................25
2.6.3 Inflammatory Cells in AAA ........................................................................27
2.6.4 The Role of Other Leukocytes...................................................................31
2.6.5 Proteolytic Enzymes in AAA......................................................................31
2.6.6 Oxidative Stress........................................................................................34
2.6.7 Smooth Muscle Cell Apoptosis..................................................................35
2.7 Hemodynamics and Site-Specificity of Aneurysm Formation ................................... 36
2.7.1 Aortic Regional Variation and Disease Relevance ....................................36
2.7.2 HOX Genes and the Vasculature ..............................................................39

v

CHAPTER 3 – MATERIALS AND METHODS..........................................................................41
3.1 Human Research Compliance ................................................................................. 41
3.2 Genetic Association and Sequencing of Functional Positional Candidate
Genes ..................................................................................................................... 41
3.2.1 Human Samples for Genotyping and Sequencing.....................................41
3.2.2 DNA Isolation and Whole Genome Amplification.......................................41
3.2.3 RNA Isolation and cDNA Synthesis...........................................................42
3.2.4 Genetic Association Study ........................................................................42
3.2.5 Sequencing of Functional Positional Candidate Genes .............................43
3.2.6 Functional Analysis of Sequence Variants ................................................44
3.3 Microarray Expression Profiling ............................................................................... 44
3.3.1 Baboon Tissue Samples for mRNA Expression Profiling...........................44
3.3.2 RNA Isolation and Quality Control.............................................................44
3.3.3 Microarray Analysis...................................................................................45
3.4 Protein Analyses ..................................................................................................... 46
3.4.1 Tissue Samples Used in Protein Expression Studies ................................46
3.4.2 Preparation of Protein Homogenates ........................................................47
3.4.3 Western blotting ........................................................................................48
3.4.4 Blot Quantification and Statistical Analysis................................................49
3.4.5 Immunohistochemistry ..............................................................................50
3.4.6 Cell Culture and Immunofluorescence ......................................................51
CHAPTER 4 – RESULTS .........................................................................................................52
4.1 Identification of Potential Risk Alleles in Functional Positional Candidate
Genes ..................................................................................................................... 53
4.1.1 Selection of Functional Candidate Genes .................................................53
4.1.2 Candidate Gene Association Study...........................................................53

vi

4.1.3 DNA Sequencing of Exons in Candidate Genes with Putative
Association...............................................................................................55
4.1.4 Predicted Functional Changes ..................................................................56
4.2 Regional Gene Expression in the Aorta ................................................................... 57
4.2.1 Whole-Genome Expression Profiling of Full-Length Baboon Aortas ..........57
4.2.2 HOX Gene Expression in AAA ..................................................................59
4.2.3 HOXA4 Protein Expression in Human Aorta .............................................59
4.2.4 In Vitro Characterization of HOXA4 Protein...............................................61
CHAPTER 5 – DISCUSSION ...................................................................................................62
5.1 Genetic Association and Sequencing of Functional Positional Candidate
Genes ..................................................................................................................... 62
5.1.1 Identification of Candidate Genes in the AAA1 and AAA2 Linkage
Intervals ...................................................................................................62
5.1.2 Genetic Association Studies......................................................................63
5.1.3 Sequence Analysis of Candidate Genes ...................................................64
5.2 Identification of Regionally Expressed Candidate Genes......................................... 65
5.2.1 Spatially Expressed Candidate Genes ......................................................65
5.2.2 Expression of HOX Genes in AAA and Control Tissue..............................67
5.2.3 HOXA4 Expression in the Aorta ................................................................68
CHAPTER 6 – CONCLUSION..................................................................................................73
Appendix A – Tables.................................................................................................................74
Appendix B – Figures................................................................................................................88
References .............................................................................................................................116
Abstract ..................................................................................................................................147
Autobiographical Statement ....................................................................................................149

vii

List of Tables
Table 1: Familial prevalence of AAA based on interviews. ........................................................ 74
Table 2: Prevalence of AAA among first-degree family members based on
ultrasonography screening.......................................................................................... 74
Table 3: Power calculations for genetic association studies. ..................................................... 75
Table 4: Samples used for sequencing of CEBPG and CD22 ................................................... 76
Table 5: Samples used for sequencing of PEPD....................................................................... 77
Table 6: PCR primer pairs for CEPBG, PEPD and CD22. ......................................................... 78
Table 7: Sequencing primers for CEBPG, PEPD and CD22. .................................................... 79
Table 8: Tissue samples of baboon aorta used for microarray analysis. ................................... 80
Table 9: Human tissue samples from non-aneurysmal aortas used in assessing protein
expression of HOXA4. ................................................................................................ 81
Table 10: Human AAA samples used in immunohistochemistry of CD22 and PEPD ................ 81
Table 11: Primary antibodies used in western blots and immunohistochemical staining ........... 82
Table 12: Functional positional candidate genes studied by genetic association....................... 83
Table 13: Results of candidate gene association for SNPs in or around candidate genes
with nominal p < 0.05 ................................................................................................ 84
Table 14: Sequence changes detected by cDNA sequencing of PEPD..................................... 85
Table 15: PEPD sequence changes by sample number............................................................ 85
Table 16: Sequence changes identified by CD22 exon sequencing .......................................... 86
Table 17: CD22 sequence changes by sample number ............................................................ 86
Table 18: Genes identified by linear regression analysis of baboon microarray data............... 87a

viii

List of Figures
Figure 1: Sites of aneurysmal disease in the aorta.................................................................... 88
Figure 2: Gross appearance of an AAA..................................................................................... 89
Figure 3: Images of PCR product bands used in candidate gene sequencing........................... 90
Figure 4: Diagram of section numbering used for baboon aortas. ............................................. 91
Figure 5: Dissection of baboon aortic tissue.............................................................................. 92
Figure 6: Principle components analysis (PCA) of microarray signal data. ................................ 93
Figure 7: Representative SDS-PAGE gel of protein homogenates used in western
blotting. ...................................................................................................................... 95
Figure 8: Linkage disequilibrium (LD) plot of genotyped SNPs in CEBPG and PEPD ............... 96
Figure 9: LD plot of validated SNPs from the HapMap project in the region of CD22. ............... 97
Figure 10: Immunohistochemistry of CD22 and PEPD demonstrates expression in aortic
tissue....................................................................................................................... 98
Figure 11: Sequence variants identified by candidate gene sequencing ................................. 100
Figure 12: Predicted effects of A432T and L435F amino acid substitutions on the
structure of PEPD.................................................................................................. 101
Figure 13: Predicted miRNA binding sites in the 3’ UTR of CD22 that overlap sequence
variants identified by DNA sequencing. ................................................................. 102
Figure 14: Spatial expression changes in HOX genes in baboon aortic tissue. ....................... 103
Figure 15: HOX gene transcripts are significantly decreased in AAA tissue compared
with controls. ......................................................................................................... 105
Figure 16: Immunohistochemical staining shows HOXA4 protein in aortic tissue .................... 106
Figure 17: Aortic tissue sections from adolescent and adult donors exhibit different
staining patterns .................................................................................................... 109
Figure 18: Protein bands observed by western blot analysis. .................................................. 111
Figure 19: Western blots of HOXA4, ACTA2, and ACTB on paired thoracic and
abdominal aortic tissue samples. ........................................................................... 112
Figure 20: HOXA4 protein is significantly decreased abdominal aorta compared with
thoracic aorta......................................................................................................... 113
Figure 21: HOXA4 shows decreasing expression with age. .................................................... 114

ix

Figure 22: HOXA4 localizes to the perinuclear region in vascular cells. .................................. 115

x

1
CHAPTER 1 – INTRODUCTION

Parts of this chapter were reproduced with permission from:
Lillvis J, Lenk GM, Kuivaniemi H. Genetics of Abdominal Aortic Aneurysms. In: Aortic
Aneurysms: Pathogenesis and Treatment, Humana Press Inc., Totowa, NJ 2008.
Nischan J, Lenk GM, Boddy AM, Lillvis JH, Tromp G, Kuivaniemi H. Abdominal aortic
aneurysms- a complex genetic disease. In: Aneurysms: Types, Risks, Formation and
Treatment, Nova Science Publishers, Inc., Hauppauge, NY 2009.
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Abdominal aortic aneurysm (AAA) is a dilatation of the abdominal aorta, characterized
by degenerative changes and expansion of the entire vessel wall. AAA is the most common of a
spectrum of aortic diseases, which includes aneurysms, pseudoaneurysms and dissections.
Aneurysmal disease can occur at several sites in the aorta, resulting from variety of etiologies
(Figure 1), but the most common are infrarenal AAAs with uncertain etiology. Aneurysms
develop after an initial insult to the vessel wall, followed by slow, progressive expansion. As an
aneurysm grows, the wall will weaken further and can eventually rupture, often resulting in
massive bleeding and rapid death.
The disease burden of AAA is significant, particularly in the elderly population. Its
prevalence is approximately 2% in the general population and is as high as 10% in older men1-3.
According to mortality statistics from the Centers for Disease Control, AAA accounts for
approximately 15,000 deaths per year, making it the 17th leading cause of death4. This may,
however, underestimate the true disease burden. Since AAA is usually asymptomatic until
sudden rupture, death from undiagnosed aneurysms may be attributed to comorbid conditions,
such as coronary artery disease (CAD). Despite the grim statistics, aneurysms are easily
treatable when diagnosed early. The only currently available therapy, elective repair, either
surgical or endovascular, is highly effective, with a mortality of less than 5% as compared with
up to a 90% mortality associated with rupture5,6. In order to provide timely repair, early detection
is necessary. Yet, since universal screening has been deemed cost-prohibitive7, many
asymptomatic aneurysms are found incidentally during imaging studies for unrelated conditions.
Additionally, due to advanced age or comorbid disease, some patients may not be appropriate
candidates for surgery. Ideally, better screening strategies could identify those most at risk of
developing an aneurysm and they could be treated pharmacologically to slow or prevent
aneurysm growth.
As a multifactorial disease, AAA formation is contributed to by environmental and
genetic risk factors. Age increases susceptibility to AAA formation, as aneurysms rarely occur
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before the age of 50 and increase in prevalence with age2,3,8-11. Susceptibility to AAA also differs
by sex, with men approximately 5 times more likely to develop an aneurysm, as well as by race,
with Caucasians being at higher risk of developing an aneurysm8-14. Several modifiable risk
factors are associated with AAA including smoking, physical inactivity, atherosclerosis,
hypertension, and hyperlipidemia12. Smoking is particularly important, increasing the risk of
developing an AAA approximately 5-fold

8,10,12,15

. Surprisingly, diabetes mellitus, which is a risk

factor for other vascular diseases, has a protective effect in AAA11,12. Genetic differences also
contribute to AAA risk, with approximately 13% of AAA patients having a positive family history
of the disease16. Population-based studies show that having a family history of AAA
approximately doubles the risk of developing an aneurysm12,17.
Although there are well-described risk factors and processes known to contribute to AAA
etiology and pathogenesis, much concerning the precise mechanisms involved in initiation,
growth and rupture of AAAs is still poorly understood. AAA is invariably associated with the
presence of atherosclerosis, an association that often leads AAA to be described as a direct
sequela of atherosclerosis18. Atherosclerotic changes with age are nearly universal19, however,
whereas AAA only occurs in a subset of individuals, suggesting that there are additional factors
responsible for AAA formation20. Age-related changes in the aorta are in most cases necessary
but not sufficient for AAA formation, since most elderly individuals do not develop an aneurysm.
Smoking greatly increases the risk of developing an AAA, but its mechanism of action has not
been elucidated. Factors specific to the abdominal aorta may also contribute; AAA are several
times more prevalent than thoracic aortic aneurysms and dissections (TAAD) and have different
risk factors and pathogenesis21-23.
Most of our understanding of the mechanisms contributing to AAA is primarily confined
to the later stages of the disease, in large part due to the availability of aneurysm tissue from
elective repairs. Late-stage AAA tissue exhibits inflammatory and degenerative changes to the
entire vascular wall. The extracellular matrix (ECM), consisting of primarily of the structural

4
proteins elastin and collagen, is progressively degraded and there is loss of smooth muscle cell
(SMC) density24. Growing evidence indicates a central role for the immune system; infiltrates
containing lymphocytes, macrophages, mast cells, and neutrophils throughout the vessel wall,
especially adventitia, are a distinguishing feature of AAA. These infiltrating cells contribute to
weakening of the aortic wall through several mechanisms, including release of ECM degrading
proteolytic enzymes such as matrix metallopeptidases (MMPs) and cathepsins, induction of
SMC apoptosis and production of reactive oxygen species. Unfortunately, even with an
improved understanding of AAA pathogenesis, efforts to slow or reverse AAA growth with
pharmacotherapeutics, including beta-blockers25, statins26-29, and antibiotics30-34 have given
mixed results, and no therapies have yet been validated in large clinical trials. In order to
develop improved therapeutics, a better understanding of the specific genes and pathways
involved in AAA pathogenesis will be necessary.
One strategy to studying the molecular determinants of AAA pathogenesis is through the
identification of AAA risk loci. This strategy not only offers the possibility to find genes or
pathways relevant to AAA formation, but also to develop genetic screening to identify those at
the most risk of developing the disease. Identification of risk loci is done using genetic linkage or
association methods. Linkage analysis, which examines allele sharing between related
individuals, is a powerful method of identifying loci that exert a strong genetic effect within
families 35. Two published linkage analyses of AAA-affected relative pairs have identified regions
on chromosomes 19q13 and 4q31 as genetic risk loci36,37. The major disadvantage to these
studies, however, is relatively poor resolution, since each AAA loci contains hundreds of genes.
In contrast, genetic association studies usually identify one or two genes by examining the
association between the genotype at a polymorphic locus, usually a single nucleotide
polymorphism (SNP) and the phenotype of interest. Potential drawbacks to association studies,
however, are the need for large sample sizes and the potential for spurious association resulting
from the genetic structure of the population under study. Many genetic association studies of
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AAA have been underpowered with small sample sizes, but significant associations with
variants in genes such as AGTR1 and ANRIL have been identified using large, diverse study
populations 38,39. An additional challenge for genetic association studies is SNP selection.
Genome-wide association studies (GWAS) offer the potential for comprehensive genetic
coverage but may lose significance after correction for multiple testing. In contrast, candidate
gene association studies test fewer variants but increase the likelihood of missing relevant
variants. Combining methodologies is one potential way to identify specific genes with strong
genetic effects. For instance, testing positional candidate genes within linkage loci by
association methods has been used successfully to identify risk genes in several diseases40-43.
Additionally, positional candidates can be further prioritized using gene expression data from
disease tissue and knowledge of the gene function44.
An alternative strategy for studying the molecular genetics of a complex disease such as
AAA is gene expression profiling. Comparison of gene expression between AAA tissue and
normal abdominal aorta can identify upregulated or downregulated genes. Quantitative
polymerase chain reaction (PCR) allows for the study of the expression of one or a small
number of genes simultaneously and is useful for studying genes with good evidence for
potential disease involvement. Studies of gene expression in AAA have utilized PCR-based
methods in identifying the contribution of MMPs, cathepsins and cytokines to aneurysm
pathogenesis. In contrast, several commercially available microarray platforms allow for
examination of whole genome expression profiles and identification of transcripts not previously
identified in disease pathogenesis. By utilizing gene annotation databases such as gene
ontology (GO)45 or the Kyoto Encyclopedia of Genes and Genomes (KEGG)46, significantly
upregulated pathways or categories of genes can be identified. Three whole genome microarray
analyses of AAA have been published, which compared gene expression profiles between
aneurysmal and control abdominal aorta, ruptured and unruptured segments of AAA tissue and
blood from AAA patients and controls, respectively47-49. The former, published by our laboratory,
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identified novel expression of genes such as the gene runt related transcription factor 3
(RUNX3) and demonstrated upregulation of leukocyte signaling pathways48. One limitation of all
gene expression studies, however, is that transcript levels do not always correlate with protein
levels. Therefore, confirmation of protein expression with methods such as immunoblotting or
immunohistochemistry is necessary.
Another limitation of most studies examining gene expression from AAA tissue is that
they were not able to specifically address AAA formation since they relied on tissue from latestage disease. Since it is currently not possible to identify and obtain tissue from aneurysms
very early in their development, alternative strategies must be devised to address this question.
Identification of AAA risk loci has been proposed above as one such strategy. Additional
methods are necessary, however, since these methods may only identify a small number of
genes. Furthermore, aneurysms with a familial component may be sufficiently different from
sporadic cases in etiology. Another strategy is to identify those genes that exhibit expression
unique to the abdominal aorta. As previously mentioned, aneurysms have a propensity to form
inferior to the renal arteries in the abdominal aorta. Several characteristics distinguish the
abdominal aorta from the thoracic aorta, including ECM protein composition50, SMC lineage51
and blood flow dynamics52. Therefore, it is likely that these differences are reflected at the level
of gene expression.
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1.1 Specific Aims
Over the past 20 years, our knowledge of risk factors for AAA and the mechanisms
involved in aneurysm growth has grown dramatically. Despite these advancements, there is still
clear need for further improvements. Many cases of AAA go undetected and there have been
no effective pharmacotherapeutics developed for the disease. To address these problems, a
better understanding of the molecular mechanisms responsible for aneurysm formation is
necessary. The research presented here examines these mechanisms from two perspectives.
Specifically, the study had the following aims:
1. Determine whether AAA risk alleles are present in CD22, PEPD, CEBPG or other functional
candidate genes within the AAA linkage intervals on chromosomes 19q13 and 4q31.
a. A genetic association study was carried out by genotyping SNPs in and around ten
functional candidate genes.
b. Exon sequencing was performed on three genes with evidence of nominal
association, CD22, PEPD, and CEBPG, in order to identify additional variants for further
study.
2. Study spatial gene expression in the aorta to identify genes of potential relevance to the
localized nature to AAA.
a. A microarray screening study of entire baboon aortas was undertaken to identify
genes with regional expression in the aorta
b. Confirmation of protein expression was conducted for one gene of interest, HOXA4,
using western blots and immunohistochemical staining of human aortic tissue and in
vitro analysis of low passage aortic ECs and SMCs.
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CHAPTER 2 – BACKGROUND AND SIGNIFICANCE

Parts of this chapter were reproduced with permission from:
Lillvis J, Lenk GM, Kuivaniemi H. Genetics of Abdominal Aortic Aneurysms. In: Aortic
Aneurysms: Pathogenesis and Treatment, Humana Press Inc., Totowa, NJ 2008.
Nischan J, Lenk GM, Boddy AM, Lillvis JH, Tromp G, Kuivaniemi H. Abdominal aortic
aneurysms- a complex genetic disease. In: Aneurysms: Risks, Formation and Treatment, Nova
Science Publishers, Inc., Hauppauge, NY 2009.
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2.1 Pathology and Natural History of Abdominal Aortic Aneurysms
Aneurysms form when changes result in weakening and expansion of the entire vessel
wall. True aneurysms should be distinguished from pseudoaneurysms and dissecting
aneurysms, which occur when a tear in an artery wall causes a hematoma to form either outside
or within the wall of the vessel, but do not involve all three histological layers of a vessel. The
aorta is the most common site of aneurysm formation, but they can also form at other vascular
sites including the Circle of Willis, popliteal arteries and coronary arteries. In the aorta, AAA are
six times more common than thoracic aortic aneurysms (TAA), and approximately 80% of AAA
occur between the renal arteries and iliac bifurcation. The etiology of most AAA is not known
and they are therefore referred to as nonspecific aneurysms; nonspecific AAAs are also
commonly known as atherosclerotic aneurysms due to the presence of atherosclerotic changes.
Less common are inflammatory AAA, which are characterized by a thickened wall and
retroperitoneal fibrosis 53, as are mycotic AAAs, which form as a result of an infection of the
aortic wall, usually from Staphylococcus or Salmonella species54.
On gross examination (Figure 2), aneurysms exhibit varying size and shape18. Large
aneurysms can exceed 10 cm in diameter and may reach from the renal arteries to the iliac
bifurcation. A significant minority of cases may also have iliac artery aneurysms. Aneurysms can
be fusiform or saccular in shape. The walls of an AAA will typically show signs of thinning and
the luminal surface will have gross evidence of atherosclerotic lesions. Thrombus formation can
also be observed in the dilated region of the aneurysm.
In histological sections, several distinct features are observed in AAA. As an elastic
artery, the aorta has three histological layers, the tunicas intima, media and adventitia, with the
medial layer composed of elastic lamellae consisting of alternating layers of SMCs and elastin
fibers. As AAA progresses, there is a characteristic destruction of the elastic lamellae, with
elastic fiber fragmentation observed by Verhoeff-van Gieson staining. Loss of medial SMCs to
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apoptosis is also observed24. In the adventitial layer, there are extensive inflammatory infiltrates
as well as a loss of collagen in advanced cases of AAA55. Inflammation may also be observed in
the intima and consists of atherosclerosis-associated macrophages and T-cells. In contrast,
AAA-associated infiltrates in the outer medial and adventitial layers consist primarily of
lymphocytes but can include other leukocyte cell types 56-60. These immune infiltrates are
increasingly recognized as critical to aneurysm formation and will be discussed in detail below.
The natural history of an AAA is characterized by slow progressive growth. By the time
the aorta has expanded enough to be classified as aneurysmal, it will almost invariably continue
to increase in size until it ruptures or the patient dies of another cause. This growth proceeds
slowly; aneurysms grow only a few millimeters annually, although the rate of growth will
increase as the aneurysm diameter increases61,62.
The clinical presentation of an AAA varies significantly and depends on if and where it
has ruptured. Unruptured aneurysms are typically asymptomatic, although symptoms including
pulsations, abdominal or back pain, nausea, or symptoms of claudication or embolism may
develop from the aneurysm pressing on surrounding structures63. A majority of aneurysms
rupture into the retroperitoneal space, often presenting as the triad of back pain, hypotension
and a pulsatile mass64. Most of the remaining ruptures are directly into the peritoneal cavity,
which can quickly result in hypovolemic shock and death63. Aneurysms may also rarely rupture
into the vena cava or duodenum via fistula formation65.
2.2 Epidemiology and Risk Factors of Abdominal Aortic Aneurysms
AAA is a significant disease of aging with approximately 5-10% of individuals over the
age of 65 harboring an aneurysm. Increasing age contributes to AAA risk, as demonstrated by
both population screening and autopsy series2,8,10-12. Aneurysms are not usually detectable in
individuals under the age of 5015 unless associated with other diseases like the Marfan
Syndrome66, although there are rare exceptions67.
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Other demographic factors also modify the risk of developing an AAA. Male sex is
strongly associated with AAA risk; the prevalence of aneurysms in men is 4-6 times higher than
in women8-10,12-14. In the Aneurysm Detection and Management (ADAM) trial, a screening study
of approximately 125,000 Veterans Administration patients, females had approximately half of
the risk of developing a small aneurysm, defined as a diameter between 3 and 3.9 cm, than
males (OR 0.47, 95% CI 0.32-0.69) and one fifth the risk of developing an aneurysm 4.0 cm or
greater in diameter (OR 0.18, 95% CI 0.07-0.48)12. Caucasian race is also associated with AAA
risk. A comparison of blacks and Caucasians from the same geographic area showed fewer
aneurysms detected by screening and autopsy68. In a different study, fewer blacks presented for
treatment for aortic aneurysms and with a lower percentage of cases that were classified as
nonspecific AAA69. In the ADAM (ADAM) trial, this translated to 40-50% risk reduction in blacks
for developing both small (OR 0.62; 95% CI 0.53-0.73) and large aneurysms (OR 0.53, 95% CI
0.40-0.69)12.
There are several modifiable risk factors for AAA, with smoking having the strongest
effect. A history of tobacco use increases the odds of developing an aneurysm by 3- to 5fold8,10,12,15. Recent smoking history appears to be most important, as current smokers are at
increased risk relative to ex-smokers10. Smoking is also dose-dependent, as increased
cigarettes smoked per day, both in current and ex-smokers, as well as increased number of
years spent smoking are also associated with higher risks of developing an aneurysm10.
Many individuals with AAA will also have comorbid cardiovascular disease. As noted
above, atherosclerotic changes are seen on the luminal surface of most aneurysms.
Atherosclerosis, as well as hypertension, coronary artery disease and hypercholesterolemia,
have been identified in 30-60% of AAA patients12. On the other hand, atherosclerosis,
hypertension and hypercholesterolemia are seen in much younger patients and are far more
prevalent than AAA. Furthermore, relative to other risk factors, the contributions of these
diseases to AAA risk are modest, with odds ratios ranging 1.15 to 1.66 in the ADAM trial. This
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suggests that while these diseases may contribute to vascular injury leading to AAA formation,
their role is not specific. Interestingly, and for reasons not fully understood, type II diabetes
mellitus acts as a protective factor for AAA development11,12. This effect and many of the other
risk factors have been independently confirmed in a separate population11.
A history of physical inactivity has also been associated with AAA formation15. Exercise
is well-known to reduce the risk and improve the sequelae of cardiovascular diseases, including
hypertension, diabetes mellitus, and CAD70. With respect to aneurysms, exercise training can
decrease vascular wall stiffness71 and compared to matched controls, patients with AAA exhibit
an increase in arterial stiffness72.
2.3 The Genetics of Abdominal Aortic Aneurysms
Evidence strongly suggests that genetic risk factors also contribute significantly to AAA
risk. Aneurysms of the abdominal aorta may occur as a result of well-described genetic
disorders resulting in blood vessel weakness such as the Marfan syndrome and the EhlersDanlos syndrome66,73. However, these do not account for a significant percentage of AAA cases
and AAAs are rare compared with TAA in these patients. Clustering of AAA within families with
no detectable genetic disorder was first observed in a case report describing three brothers with
the disease74. Since then, several case series and ultrasound screening studies have supported
this observation. Approximately 10-15% of AAA patients report a positive family history (Table
1), although this percentage varies considerably by the population under study, as well as
patient characteristics (i.e. ruptured vs. unruptured, cases detected by screening vs. presenting
for treatment). Screening studies of siblings of AAA patients show similar results, with 230 of
1,723 siblings harboring an AAA (Table 2). Consistent with the increased risk of AAA in men,
brothers of AAA patients are at particular risk with an AAA present in almost 20%.
Quantitatively, family history is an important risk factor at the population level. In the
ADAM trial, only smoking history and gender had stronger effects on AAA risk than family
history (OR 1.93, 95% CI 1.71-2.18 for small aneurysms; OR 1.94, 95% CI 1.63-2.32 for large
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aneurysms)12. A study by Larsson, et al. utilized national registries of medical history, cause of
death, and family relationships in Sweden to examine AAA family history at the population
level17. Out of 3183 AAA cases identified through either the medical record or cause of death
registries, 8.4% were identified as having a family relationship with another AAA case as
compared with 4.6% of 15,943 population controls. This translates to similar risk associated with
family history as observed in the ADAM trial (OR 1.9; 95% CI 1.6-2.2)17. Furthermore, higher
risk was observed with additional affected family members, which is consistent with our
knowledge of genetic disorders.
Twin-based studies are also useful in demonstrating that a disease has a genetic
component. These studies rely on the observation that sharing of environmental exposures
does not differ between monozygotic and dizygotic twins but the number of shared alleles does.
If a trait has a genetic basis, the odds of a monozygotic twin of an AAA patient having the
disease would be higher than dizygotic twin. A study of 265 twins with AAA in Sweden
demonstrated that the odds ratio for a monozygotic twin of AAA patient developing the disease
was 71.1 (95% CI 27.5-183.4) compared to 7.6 (95% CI 3.0-19.2) for a dizygotic twin75. Seventy
percent of the total trait variance was calculated to be from genetic factors, with only 30% from
environmental factors, strongly supporting the concept that genetic factors contribute to AAA
risk.
AAA exhibits additional characteristics consistent with being a genetic disease.
Majumder, et al. and Verloes, et al. studied 91 and 313 families of AAA patients, respectively,
using a statistical approach known as segregation analysis to demonstrate that AAA is a
heritable trait76,77. Segregation analysis compares the observed pattern of disease in a set of
pedigrees versus the patterns expected from different genetic models and determines the model
that most likely explains the observed data. Both of these studies concluded that a major gene
effect was responsible for AAA risk within families, but disagreed on the mode of inheritance,
one identifying a recessive model and the other a dominant model76,77. One possible
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explanation for this discrepancy is that different genes may be responsible for increased AAA
risk in different families. In addition to the formal statistical analyses supporting the genetic
nature of AAA, several collections of AAA families have been reported, the largest one
describing 233 families with multiple affecteds78.
AAA also demonstrates characteristics of being a multifactorial genetic disease with
respect to gender. One feature of multifactorial diseases is gender-discrepancy in prevalence, a
phenomenon that is well documented in diseases such as pyloric stenosis, many congenital
heart defects, neural tube defects and cleft lip79. As noted above, males are at increased risk of
developing an aneurysm. However, when females do present with an aneurysm, it is
presumably due to having a greater genetic or environmental liability and therefore should
represent the more severe end of the spectrum of disease80. This is supported by the fact that
females have an increased aneurysm growth rate81, have increased operative mortality for both
intact and ruptured AAAs compared to males82,83, and there is increased inflammation in the
walls of resected aneurysms from female patients84. Additionally, if this liability is genetic, one
would expect to see a higher prevalence among females inheriting the mutations. In one study
of 542 AAA patients, the 82 (15.1%) patients who had a positive family history were compared
to the 460 sporadic cases85. When examined for gender distribution, the sporadic cases
presented with an 86%:14% ratio of males to females, whereas 35% of the familial cases were
female, despite no differences in smoking, hypertension, or coronary artery disease. An
investigation of rupture rates of the patients with a positive family history, as well as their firstdegree relatives, found that 22/73 (30.1%) aneurysms in females ruptured as compared to
23/136 (16.9%) in males85. Finally, it was also found that the males with a family history were
younger than the males with sporadic aneurysms, another characteristic consistent with genetic
diseases85. Similar results were reported in a different study of 300 AAA patients that showed a
higher rate of rupture among familial cases of AAA86.
2.4 Clinical Diagnosis and Management
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Diagnosis of an AAA is made by imaging studies in either symptomatic individuals or
incidentally during a test for an unrelated condition. AAA is typically defined as an absolute
infrarenal diameter greater than 3 cm, although alternative diagnostic criteria may be used, such
as an infrarenal to suprarenal diameter ratio greater than 1.2. Ultrasound (US) is the modality of
choice for detection and monitoring, as it is inexpensive, has high sensitivity and specificity and
does not require exposure to ionizing radiation. US is subject to problems in overweight or nonfasting individuals, potentially missing the presence of an AAA87. Computed tomography (CT)
and magnetic resonance imaging (MRI) are typically not used as screening tools, but offer
better resolution than US and provide a more complete picture of aneurysm geometry and
location.
Therapy for AAA is currently limited to surgical repair. Two major surgical approaches
are utilized, open surgical grafting and endovascular stent-grafting88. Each of these approaches
has advantages and there is currently ongoing debate about their appropriate uses.
Endovascular repair is minimally invasive and has slightly lower mortality at 1 month postprocedure, but mortality at 2 years is comparable89,90. Endovascular repair is more expensive,
suggesting that open repair may be more suitable91. It is possible that endovascular repair may
be appropriate for some individuals unfit for open repair, but a comparison of endovascular
repair versus no intervention in 400 such patients showed higher costs associated with
treatment and no benefits in all-cause mortality92. It has also been suggested that endovascular
repair may be appropriate for repair of small aneurysms93-95, but the recent results of the
Positive Impact of Endovascular Options for Treating Aneurysms Early (PIVOTAL) trial, a
randomized trial comparing endovascular repair to ultrasound monitoring in 728 patients with
AAAs between four and five centimeters in diameter demonstrated neither benefit nor harm
from early repair96.
Optimal management of AAA relies on diagnosis and therapy prior to aneurysm rupture.
Approximately 50% of individuals with a ruptured AAA die prior to reaching the emergency room
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and a significant proportion of the other 50% do not survive the repair operation6. In
comparison, elective repair has a mortality of less than 5%5. Since most unruptured AAAs are
asymptomatic, however, there has been interest in developing screening protocols for AAA.
Similar to colonoscopies and mammograms for detection of colon and breast cancers,
respectively, population screening of elderly individuals with abdominal ultrasound has been
proposed for AAA. Large trials screening for AAA suggest that it may be cost-effective in men
65-75, but would likely not be for whole population screening7,97-100. Rather, currently proposed
screening guidelines are targeted, incorporating additional risk factors, including smoking and
family history7,101-104. Going forward, one possibility is that a better understanding of AAA genetic
risk variants would help to identify those most at risk of developing an aneurysm.
Even with a diagnosed AAA, appropriate timing of surgical repair is problematic. Despite
low mortality, elective repair is not risk-free. Several factors are associated with an increased
risk of rupture, including smoking and female sex, but the most clinically useful parameter is
aneurysm size61. Population trials have established an aneurysm diameter of 5.5 cm as having
a risk of rupture greater than the risk of repair61. Not all of the factors involved in aneurysm
rupture are known and rupture of small aneurysms is possible. Imaging technologies show
some potential to identify high-risk aneurysms105, but the cost associated with these tests may
be high.
Ideally, aneurysm rupture or even formation could be prevented using medical therapies
aimed at slowing or reversing aneurysm growth. Given an annual average growth rate of 2.6
mm61, a 3 cm aneurysm will take over five years to reach 5.5 cm, indicating that even a modest
reduction in aneurysm growth rate might forestall rupture by several years. At this time,
however, there are no specific pharmacotherapeutics for AAA. Several drug classes have been
studied, including beta-blockers25, statins26-29, and macrolide31 and tetracycline32-34 antibiotics. In
particular, use of statins, roxithromycin and doxycycline have been associated with reduced
growth rates. These studies, however, were small (32-150 enrolled patients) and did not
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necessarily achieve significance. Furthermore, none of these studies has yet been validated by
a large clinical trial nor have reductions in mortality been demonstrated. Finally, it is not clear for
currently available drugs whether the benefits in growth reduction will outweigh the risks/side
effects of long-term use. Going forward, development of targeted therapies for AAA remains of
great interest for research and the clinic.
2.5 Genetic Studies for Identifying Complex Disease Loci
Despite extensive evidence for a genetic component in AAA, our understanding of the
genetic components of AAA risk is still incomplete. In order to identify susceptibility loci for
complex diseases like AAA, two general study designs have been employed: linkage analyses
and genetic association studies. These studies are similar in concept in that they utilize naturally
occurring sequence variants in order to identify these loci. Linkage analyses and genetic
association studies rely on linkage and linkage disequilibrium (LD), respectively, two closely
related but distinct genetic concepts. Linkage refers to the phenomenon of two genetic loci
having an increased probability of being coinherited35. If there is a large distance between two
loci on a chromosome, the chance of a crossing-over event occurring between the loci
increases until all four possible combinations of alleles are equally likely to be inherited. In this
instance, the proportion of gametes where recombination has occurred, also known as the
recombination fraction (denoted θ), is 1/2, indicating independent segregation at the two loci. In
contrast, for two loci in close proximity, the probability of a recombination event occurring
between the two loci decreases, reducing θ to value between 0 and 1/2, indicating the two loci
are in linkage. In contrast, LD is a population level concept. If an association exists between two
loci at the population level, indicating that they have been coinherited over time from a distant
ancestor, the loci are in LD.
Linkage is utilized in identifying disease loci by testing for linkage between a marker
locus, usually a microsatellite marker, and a locus inferred by phenotype. Typically, the linkage
statistic is expressed as a logarithm of odds (lod) score, which describes the likelihood that
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observed data is the result of linkage rather than by chance, with a lod score of 3 commonly
being defined as significant evidence of linkage. Several linkage methods exist for disease gene
identification, including model-based and model-free analyses. For diseases with large families
with affected members in at least three generations, model-based analyses, meaning a genetic
model is specified, can be utilized. However, this approach is not appropriate for AAA, since
many individuals diagnosed with AAA have parents who have died but children too young to
develop an aneurysm, therefore making it difficult to find two, let alone three, generations living
with aneurysms. Instead, model-free analyses using relative pairs can be utilized. For any two
related individuals, it is possible to calculate the probability that they share an allele at a given
locus identical by descent (IBD), meaning it is inherited from a common ancestral chromosome.
Sibling relationships are particularly useful, since sharing of 0, 1, or 2 alleles IBD is possible,
although other relationships such as cousin-cousin or child-grandparent can be used.
Furthermore, sib-pair linkage analyses avoid the problem of multiple generations, since they
require only two individuals from one generation of each family to be alive and willing to
contribute to the study. Another problem with conventional model-based linkage analyses rely
on the ability to accurately distinguish between affected and unaffected individuals. Since AAA
is a late-age-at-onset disease, its incidence increases with age, a phenomenon known as agedependent penetrance. However, by using a type of sib-pair analysis known as affected sib-pair
(ASP), problems of penetrance are avoided because all subjects being studied have been
diagnosed with the disease.
Genetic association studies test for an association between an allele at a locus and a
phenotype of interest within a population35,106. Genetic variants, in this case single nucleotide
polymorphisms (SNPs), are genotyped in cases and controls and tests of association based on
either genotype or allele frequencies are performed. If the frequency is statistically higher or
lower in the cases, it is suggestive of a disease contributing or protective effect, respectively.
Although the risk variant may be among the variants tested, often this variant has not been
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identified. Instead, genetic association studies assume that an associated variant is in LD with a
variant with true functional effects. Identifying the variants that contribute to disease risk
requires an extensive analysis of the surrounding genomic sequences, which is often beyond
the scope of the study. Tests of association can also be tested on the collective genotypes of
several SNPs, or haplotype, since it is possible that the disease variant has been inherited over
time with a group of SNPs on a section of a chromosome even though it may not be in LD with
any single variant.
Two study designs are typically employed in genetic association studies, candidate gene
approaches and the genome-wide association study (GWAS). Candidate gene association
studies rely upon knowledge of the disease to identify genes plausible in the disease
pathogenesis. These can be performed on a relatively smaller number of samples but will not
identify variants in genes not known to be involved in the disease. On the other hand, GWAS
requires even larger samples sizes, but can give a better understanding of the genetic
architecture of diseases like AAA107. They are also more feasible than family-based studies for
complex and deadly diseases such as AAA, since samples from extended families are not
required.
Linkage analyses and genetic association studies each have advantages and limitations
for identification of susceptibility loci. Since linkage analyses rely on familial aggregation of a
disease, they are most useful for identifying a single locus (or group of interacting loci) that
confers an increased risk of developing the disease35. Linkage analyses tolerate allelic
heterogeneity, given that each risk variant is linked to the markers being tested, but can lose
power with locus heterogeneity. In contrast, genetic association studies identify loci with the
greatest contribution to disease risk in the population meaning that even variants conferring a
high relative risk may not be detectable by association if they are rare. Conversely, low risk
alleles may be detected if they are sufficiently common in the population (a minor allele
frequency or MAF of greater than 10%). Association studies are robust to locus heterogeneity,
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given that each locus has a sufficient population effect size, but the power to detect association
may be significantly diminished in the presence of allelic heterogeneity.
Another disadvantage of genetic association studies is the higher potential for detecting
spurious associations. Although false positives are certainly a concern with linkage analyses of
complex traits, poor study design has the potential to create false positives in association
studies. In particular, selection of controls for genetic association studies must be done with
care. If independent samples of affected and unaffected individuals are used, factors such as
population stratification can lead to mathematical associations that have no relationship to the
underlying genetics of the disease being studied. Several approaches exist to address this
problem, such as the use of spouses as controls in order to assure that case and control
populations originate from similar ethnic and socioeconomic groups and share similar
environmental factors. On the other hand, using “over-matched controls” or “supercontrols” will
lead to difficulty in estimating the population attributable risk for the identified genetic variants.
For this reason, some investigators advocate the use of population-based controls
representative of the “general” population in the geographic area where the study is performed.
In such studies, means for testing for potential stratification must be devised, and the so-called
“genomic control” method has been used widely. In this approach, stratification can be tested by
using genetic markers genotyped from other chromosomal regions

108

. Alternatively, genetic

markers known to show population differences can be used to show that the case and control
populations do not differ at those markers even when an association is detected in a specific
candidate gene being tested 109.
Sample size is also a concern for genetic studies. Generally, linkage analyses can be
successful with fewer participants if one can obtain samples from families with many affected
individuals. In contrast, association studies with fewer than 250 cases and 250 controls must be
viewed with skepticism, because of a lack of statistical power. Even larger sample sizes are
needed to identify variants with low allele frequencies or small relative risks and to investigate
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gene-environment interactions. Table 3 shows power calculations demonstrating sample sizes
necessary for a range of genetic risks and allele frequencies. Yet another potential complication
is multiple testing, since most studies test a study population for multiple SNPs in several
genes. In the case of a GWAS, a p-value of 5x10-7 or lower may be necessary to declare
significant association after correcting for multiple testing. Two-phase studies are one strategy
to reduce these complications; a preliminary screening of all variants is first carried out and
used to rank the most significant variants to be tested in a second, independent population. This
approach reduces the number of tests being done in the follow-up study. It must be emphasized
that replication of the findings in an independent sample set is extremely important to eliminate
false positives, although it is plausible that population-specific disease susceptibility alleles exist
and that replication in a different ethnic population will not support the initial findings. Detailed
recommendations on how to design, conduct, interpret and report on genetic association studies
have been published recently107.
2.5.1 Linkage Analyses of AAA
The use of linkage analysis to identify the genetic causes of lethal, late-age-at-onset
diseases, such as AAA, has been difficult at best and has required several technological
advancements to make the undertaking of such studies a reality. First, the use of noninvasive
diagnostic imaging, such as ultrasonography screening studies carried out on the relatives of
AAA patients, has allowed the identification of far more family members with AAA prior to
rupture (Table 2). As a result, there are far more living, affected members available for genetic
studies. Second, the identification of highly informative markers that can be easily analyzed
using PCR has greatly enhanced the power of any linkage study. Third, the large number of
linkage studies being performed on complex human diseases has refined and advanced the
methods and models for linkage analyses. Fourth, there have been theoretical and applied
advances in the linkage methodology itself 35.
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Two published reports have identified genetic loci linked to AAA using affected relative
pair (ARP) linkage methods 36,37. In the first published linkage analysis of AAA, Shibamura et
al.36 used ARP linkage analysis to carry out a genome-wide screen, identifying linked regions on
chromosomes 4 and 19. This analysis was carried out in two phases using 235 ARPs (213
ASPs) from 119 families with at least 2 individuals per family (mean=3.2, range 2-7). In the first
phase, genomic DNA from 75 ARPs (62 ASPs) in 36 families was used in a whole genome scan
of 405 microsatellite markers. From the initial scan, 12 regions were identified as significant. In
the second phase, additional microsatellite markers in those 12 regions were genotyped using
the original set of ARPs and 160 additional ARPs (151 ASPs). The combined data were then
analyzed using sex, number of affected individuals, and their interaction as covariates to allow
for genetic heterogeneity. This analysis showed two regions with significant linkage, one on
chromosome 19q13 with a lod score of 4.64 and another on chromosome 4q31 with a lod score
of 3.73. A second study by van Vlijmen-van Keulen et al.37 also demonstrated linkage to
chromosome 19q13 (non-parametric, multipoint linkage score = 3.95) by a different statistical
method when analyzing 22 ASPs from three large Dutch families. However, when 79 additional
ASPs from 55 families were included in the analysis, this method failed to demonstrate linkage,
likely due to genetic heterogeneity. As result of these linkage analyses, the chromosome 19 and
4 loci have been designated as the AAA1 and AAA2 loci, respectively, in the Online Mendelian
Inheritance in Man (OMIM) database.110. It is of interest to note that DNA linkage studies on
TAAD have identified completely different genetic regions suggesting that the two aortic
aneurysm subtypes are genetically different111.
2.5.2 Genetic Association Studies of AAA
There have been a fair number of genetic association studies for AAA, many of which
have been summarized elsewhere16. Most studies have used a candidate gene approach by
selecting SNPs from genes with known or putative function in AAA, whereas only one genomewide association study has been published to date112. It is important to note that many early
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association studies were small and did not have adequate power to definitively exclude or prove
an association. Furthermore, in several instances, evidence of association in one population has
not been replicated by studies in a different population. Possible explanations for these
discrepancies are variation in genetic risk factors between populations, and false positives or
false negatives from small sample sizes (type I and II errors).
Candidate genes that have been studied for association in AAA are involved in a variety
of physiological and disease processes. Genes involved in cardiovascular function, extracellular
matrix composition and breakdown, and immunity have all been investigated. The best evidence
for association is probably with cardiovascular risk genes. The largest genetic association study
to date on AAA demonstrated a significant association with a variant on chromosome 9p21
using 2017 cases and 16,639 controls (OR=1.31, p=1.2x10-12)38. A study of polymorphisms in
the renin-angiotensin system (RAS) by Jones and colleagues showed significant association
with the C allele at amino acid 1166 of the angiotensin II receptor 1 (AGTR1) gene using 1226
AAA cases and 1723 controls from three geographically distinct populations from New Zealand,
Australia and the United Kingdom39. Additionally, the same study demonstrated marginal
association with a deletion in intron 16 of angiotensin converting enzyme (ACE). Association
with these polymorphisms was also reported in a meta-analysis, as was association with
polymorphisms in interleukin 10 (IL10), MMP3 and 5,10-methyltetrahydrofolate reductase
(MTHFR) genes113. Two studies using 250 cases and 250 controls from the Italian population
reported evidence of association with the ACE polymorphism114 and with a variant in the nitric
oxide synthase 3 (NOS3) gene115.
Despite identification of some risk variants for AAA, there is still much to be identified
concerning AAA genetic risk. Evidence of association with several polymorphisms has not been
verified in large study populations. Even where there is strong evidence, the relative risk for
each polymorphism is relatively low, suggesting that there are many more similar
polymorphisms to be identified. Several of these polymorphisms are also non-specific for AAA;
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the 9p21 variant has been associated with CAD and IA38 and RAAS system variants have been
extensively studied in other cardiovascular diseases such as heart failure116,117, CAD118,
stroke119.
New strategies will be necessary to identify additional variants in the future. GWAS
offers some promise; the one published GWAS studying AAA identified association with SNPs
near the gene contactin 3 (CNTN3), which had not been previously indicated in AAA112.
Evidence of association was replicated by the authors using an independent set of cases and
controls. Another group failed to replicate the original findings in a separate population, but did
identify nominal association in different SNPs within CNTN3. These results did not reach
genome-wide significance, however, suggesting additional study may be necessary at this
locus120. An alternative strategy for identifying risk alleles is combining linkage and association
results. This approach has been successful in identifying risk variants for several diseases, such
as prostate cancer40, osteoporosis43, schizophrenia42 and myocardial infarction41. Linkage
results are less susceptible to confounding factors such as population stratification so even
evidence of a weak association within a linked region is more likely to represent a real genetic
effect. Furthermore, by using families enriched for the aneurysm phenotype, variants in linked
regions may be more specific for the aneurysm phenotype. Variants within linked regions are
more likely to be rare, making them of less utility at a population level.
2.6 Mechanisms of AAA Formation
2.6.1 The Immune System in AAA
Inflammation and the immune system has long been recognized in a subset of
aneurysms known as inflammatory aneurysms (IAAA) but the contribution of the immune
system to the pathogenesis of nonspecific AAA was recognized only within the past two
decades121. The first description of immune infiltrates in nonspecific AAA was a study by Koch
and colleagues in 199055, where the presence of macrophages and T- and B-lymphocytes in
AAA tissue was demonstrated by staining with the cell specific markers CD11c, CD3 and CD19,
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respectively. They were also first to observe that, despite the presence of atherosclerotic
changes in aneurysm tissue, AAA and aortoocclusive disease (AOD) have distinct
immunological phenotypes. Both diseases have similar intimal layers, with atherosclerotic
plaques containing macrophage-derived foam cells interspersed with T-cells and a small
number of dendritic cells and macrophages. AAA, however, has the additional transmural
component, with significant adventitial inflammation infiltrating into the outer media.
Conventionally, transmural inflammation in vascular disease has been explained in an
“inside out” manner, meaning that inflammatory cells infiltrate into the aortic wall from the intima.
This is supported by the presence of neovascularization at the interface of atherosclerotic
plaque and the media of the aorta where vasa vasorum are scarce122. This neovascularization
could plausibly provide a route for infiltration of the media and adventitia leading to aneurysm
formation.
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inflammation123,124. This hypothesis states that vascular injury may cause inflammatory cells to
accumulate in the adventitia that then work their way towards the lumen. An example of this
process is restenosis following balloon angioplasty where early inflammation occurs in the
adventitia and then progresses inwards 124. Following injury, neovascularization occurs in the
outer layers of the vessel, subsequently allowing greater recruitment of immune cells into the
adventitia. This may be particularly applicable to AAA development, as the abdominal aorta has
fewer vasa vasorum and may therefore be more prone to an angiogenic response to injury and
greater immune infiltration. Similar to injury from balloon angioplasty, a recently reported porcine
model of AAA requires balloon injury of the aorta as well as luminal treatment with elastase to
induce aneurysm formation125. This indicates that adventitial injury may be necessary in addition
to intimal inflammation for AAA formation.
2.6.2 Expression Profiling of AAA Tissue
Whole genome expression profiling of AAA tissue confirms the importance of the
immune system in AAA pathogenesis. Expression profiling is the characterization of a tissue by
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identifying which genes are expressed in it and how highly they are expressed. Expression
profiling can be done through several methods, but the current standard is whole-genome
microarray platforms available from several manufacturers. Microarray experiments are
expensive but much cheaper per gene and use less genetic material. Microarray experiments
compare gene expression patterns between tissues or cells, such as between an aneurysmal
aorta and a non-aneurysmal one. The changes in gene expression can then be used to identify
biological processes relevant to the disease being studied. This can be done by categorizing
differentially expressed genes by function, such as GO category45 or KEGG pathway46, and
determining the categories or pathways that are statistically enriched.
Lenk et al. reported the only whole genome comparison of AAA and control aorta using
two different microarray platforms48. From a reference list of 18,057 genes common to the two
microarrays, 3,274 genes were differentially expressed between AAA (n = 7) and control tissue
(n = 7), even after correction for multiple testing. Differentially expressed genes included ones
previously identified in AAA tissue, including several proteases and cytokines, as well as new
ones such as RUNX3 and SOST. Analysis of the differentially expressed genes using KEGG
pathways showed several pathways related to immune function to be enriched in AAA, such as
“leukocyte transendothelial migration” and “T cell receptor signaling pathway”.
Another whole genome microarray study on AAA by Choke and colleagues used pooled
RNA samples from tissue at the site of rupture from 10 aneurysms and compared this with
pooled RNA isolated from the anterior sac of the same aneurysms47. One hundred thirty-nine
genes were identified as statistically different (p<0.005) with a fold change of 2.5. Genes
involved in immune response and signal transduction were the most significantly enriched,
including selectin E (SELE), PTGS2 (also known as COX2), and interleukins 6 and 8 (IL6, IL8).
A third whole genome microarray comparing gene expression in the blood of AAA patients and
matched controls has also been published, finding changes in genes associated with lipid
metabolism and oxygen transport49.
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Although microarrays are potentially powerful tools for studying diseases like AAA, they
are also subject to some limitations. First, similar to any gene expression analysis, sample
replicates are necessary to account for sample variability. This can be problematic if the cost of
the microarrays is prohibitive or if obtaining multiple tissue samples is difficult. Another limitation
is incomplete annotation of gene function; GO categories and KEGG pathways are only useful
for genes with known function. Additionally, microarrays, as well as other gene expression
methods, only test for levels of mRNA and may not represent what is occurring at the protein
level. Therefore it is important that gene expression findings be confirmed using different
methods such as immunohistochemistry or protein blotting. Finally, there are several statistical
considerations for the analysis of microarray data such as how to define differential expression
or account for the large number of false positives generated when looking at thousands of
genes. Time-course and other longitudinal analyses require additional considerations, both with
respect to significance analysis and in defining what constitutes an expression pattern of
interest.
2.6.3 Inflammatory Cells in AAA
The immune response in AAA is diverse with inflammatory infiltrates containing a varied
population of leukocytes, including B- and T- lymphocytes, as well as natural killer and natural
killer T cells, macrophages, dendritic cells, mast cells and polymorphonuclear leukocytes
(PMNs). By far the most numerous are lymphocytes, which are located throughout the vessel
wall. Most of these are T-cells, which can be found in both the adventitia and intima, but there is
also a large proportion of B-cells found in the adventitia, another feature that distinguishes AAA
from AOD, which has minimal B-cell involvement56. NK and NKT cells have also been identified
in smaller numbers, but may have an important role in aneurysm pathogenesis (see below)56,57.
Characterization of the lymphocyte populations in aneurysm tissue has demonstrated a
role

for

adaptive

immunity

in

AAA56,57,126.

Consistent
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immunohistochemical staining, a majority of lymphocytes identified by flow cytometry are T-
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lymphocytes (~58-80%). Comparison with peripheral blood T-cells shows a similar ratio of
CD4/CD8 positive T-cells, with approximately two thirds of T-cells from AAA tissue expressing
CD4. Significantly more aneurysmal T-cells than peripheral blood T-cells express CD69 and
HLA-DR, which are markers of activation by antigen exposure56,126. Additionally, an increased
number of aneurysmal T-cells exhibit a memory phenotype, as demonstrated by CD45RO
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–

CD45RA staining56,126. Findings in B-lymphocytes are similar, with increased cells in AAA tissue
staining for the activation markers CD69 and CD80 and the memory marker CD2756,57. This
activated, memory phenotype suggests an ongoing, antigen-driven response may be
responsible for driving inflammation in AAA. This is further supported by the differences
between AAA and peripheral blood lymphocytes, which show that specific lymphocyte
populations are recruited into the aneurysm wall56.
In histological sections, adventitial lymphocytes can be found arranged as lymphoid follicle-like
structures, composed of B-cell germinal centers surrounded by T-cells56,127. Bobryshev and
colleagues127 found these structures in just over 50% of AAA tissues examined (17/31) and
identified them as hypertrophied vascular-associated lymphoid tissue (VALT), which are
analogous to mucosa-associated lymphoid tissue (MALT) in the gut and lungs. Consistent with
the role of MALT in antigen presentation, cell-to-cell contacts between T-cells and dendritic cells
were identified by electron microscopy, further supporting the possible role for an antigen-driven
immune response in AAA.
Given the evidence for AAA being an antigen-driven disease, it has been suggested that
aneurysms are a chronic autoimmune disorder in which an aortic antigen drives inflammation. A
study by Tilson showed IgG from aneurysm samples reacting to an 80 kDa protein found in the
aortic wall128. Sequence analysis of this protein showed homology to microfibrillar proteins
present within bovine and porcine aortas. Immunohistochemical staining using these AAAderived IgG showed binding to a collagen associated protein in the adventitial ECM129. These
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results suggest that inflammation directed against this protein or other constituents of the aortic
wall may contribute to AAA development. An alternative hypothesis is that chronic infection,
such as with Chlamydia pneumoniae or cytomegalovirus, may drive the immune response in the
AAA wall, either directly by the presence of the pathogen or through molecular mimicry. C.
pneumoniae has been extensively researched, with studies producing a variety of evidence
suggesting its presence in the aneurysm wall130-138, although other studies have failed to detect
C. pneumoniae DNA139,140 and C. pneumoniae IgG titers do not correlate with AAA141,142. The
combined results of these studies indicate that C. pneumoniae is likely not necessary or
sufficient for AAA formation but that it may play a role in sustaining the immune response in
aneurysmal tissue.
If AAA is antigen-driven, one would expect to detect a limited antibody or T-cell
repertoire directed against these antigens. PCR-based assessments of the TCR β-chain and
immunoglobulin heavy chain genes demonstrating unrestricted usage of the gene repertoires
suggest this may not be the case143. In contrast, a study by Platsoucas and colleagues showed
multiple identical α, β, γ, and δ chain transcripts in AAA tissue by cloning and sequencing of the
TCR repertoire, indicating at least some degree of clonality, since it is unlikely to observe
multiple clones with the same sequence by chance121,144.
+

Given that CD4 helper T-lymphocytes are the predominant leukocyte in aneurysms,
another question that has been posed by investigators is whether this represents a Type 1 (Th1)
or Type 2 (Th2) T-cell response. Conventionally, Th1 cells drive cell-mediated immunity by
stimulation of macrophages and CD8+ T-cells and Th2 cells stimulate B-cells to produce
antibodies, including IgA, directed at specific antigens, for which evidence of both exists in AAA.
Based upon histological findings, the significant macrophage presence in AAA tissue might
suggest that there is a Th1 response driving macrophage recruitment. Conversely, replicating Bcells within VALT and their colocalization with dendritic cells, as well as the presence of plasma
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cells with Russell bodies, provide evidence for a Type 2 response58,127, although the production
of opsonizing antibodies by B-cells is a characteristic of Type 1 responses. These responses
also have distinct cytokine profiles. Galle and colleagues126 used quantitative RT-PCR to study
expression of the Th1 and Th2 cytokines IFNG and IL4, respectively, and found increased IFNG
expression in aneurysmal compared to control tissue but no increase in IL4, suggesting a Th1
response. Additionally, expression of the Th1-associated transcription factor T-bet (TBX21) was
also significantly increased whereas GATA3, a Th2-associated transcription factor, was not. In
contrast, Schönbeck and colleagues145 found significant amounts of Th2 cytokines IL4 and IL10
by immunohistochemistry and western blotting but no evidence of a Th1 response. To explain
these conflicting results, Shimizu and colleagues146 have proposed a model that involved a Th1
response early in atherogenesis and a shift to a Th2 response later in aneurysm development.
One complication, however, is that some studies do not distinguish between the intimal and
adventitial infiltrates, and cytokine production might vary from layer to layer.
More comprehensive studies of cytokines in AAA have addressed the question of T-cell
response in greater depth. Lindeman, et al. used several protein and mRNA detection methods
and found Th1 cytokine genes IL2, IFNG, IL1A, and IL1B as well as Th2 cytokine gene IL13
were significantly increased in AAA over AOD147. Another study demonstrate ex vivo T-cells
production of primarily Th1 cytokines but also Th2 cytokine IL557. Array-based analyses add
further evidence to this hypothesis. A cytokine protein array study by Middleton and
colleagues148 comparing AAA versus controls found evidence of increased expression of Th1
cytokines TNF, LTA, and CCL2 and increased Th2 cytokine IL10, a result that was fairly
consistent with the microarray expression profile in Lenk, et al48. Since IL10 is also produced by
some Th1 cells, this suggests the Th1 response is predominant. Neither study, however, found a
statistically significant increase in levels of Th1 cytokines IFNG, IL2, or CSF2. In summary, these
combined results suggest that T-cell response in AAA may vary from individual to individual or
by the progression of the disease, or that AAA T-cells represent an intermediate phenotype
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capable of producing both Th1 and Th2 cytokines57.
2.6.4 The Role of Other Leukocytes
Other non-lymphocytic immune cell types have been implicated in AAA. As producers of
proteolytic enzymes such as MMPs and cathepsins, macrophages have been considered
particularly important. They are primarily found in the intima, but are also detectable in the
adventitia. By flow cytometry, macrophages represent only a small percentage (~2%) of
leukocytes, although this may be an artifact of cell isolation from tissue56,57. In addition to their
direct involvement in ECM breakdown, macrophages also produce several pro-inflammatory
cytokines and chemokines including IL1B, TNF, CCL2 and IL8, all of which show increased
production in aneurysmal tissue48. Finally, macrophages produce additional biologically relevant
molecules such as prostaglandins, which can stimulate IL1B synthesis and produce modulating
effects on SMCs, and syndecan-1, a proteoglycan with functions in tissue repair122,149,150.
Another cell type that may have a small yet critical role in aneurysm development is the
mast cell. Although mast cells are typically associated with IgE mediated immunity and allergies,
they produce several substances, such as histamine and heparin that could help drive
inflammation in AAA. Mast cells are increased in AAA tissue compared with control aortas, and
are found in the adventitial layer associated with microvessels59,151,152. Treatment with a mast
cell derived peptide, adrenomedullin, decreases collagen production in cultured fibroblasts from
AAA59. Animal models also suggest a role for mast cells in AAA pathogenesis, as aneurysm
formation is inhibited by mast cell knockout in both the elastase and CaCl2 mouse models of
AAA153.
2.6.5 Proteolytic Enzymes in AAA
Infiltrating immune cells, including mast cells, macrophages and PMNs, as well as SMCs
are able to secrete a variety of enzymes that degrade the ECM. The most studied are the
MMPs, and their inhibitors, the tissue inhibitors of metalloproteinases (TIMPs), although other
families of enzymes, such as the cathepsins, serine elastases and plasmin, have been studied.
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The MMPs are a family of related enzymes that break down ECM components including elastin
and collagen, although each MMP targets a different repertoire of substrates123,154,155. MMPs
have the necessary function of degrading damaged ECM so that new matrix can be
regenerated, but can also quickly cause tissue damage if unregulated. Therefore, MMPs are
regulated by several mechanisms: by transcription in response to cytokines and growth factors,
by secretion in inactive zymogen form, and by inhibition by TIMPs123. TIMPs are secreted
proteins that bind to activated MMPs. MMPs and TIMPs are often secreted together so as to
prevent excess MMP activity. Immunohistochemical analysis of AAA tissue shows that the MMP
to TIMP ratio is increased, suggesting that the balance between the two types of proteins
influences aneurysm development156,157.
MMP2 and MMP9, also known as gelatinase A and B, respectively, are two MMPs which
specifically cleave gelatin, types IV and V collagen, and fibronectin155. More importantly, MMP2
and MMP9 are able to efficiently cleave elastin. Elastin is the most abundant protein in the
abdominal aorta, accounting for 30% of the aorta by weight122. The elastin structure of a blood
vessel is formed during development and elastin production does not continue in adulthood122.
Under normal physiological conditions elastin is quite stable158, making the breakdown of elastin
in aneurysms particularly striking. The primary structural role of elastin is load bearing; it
provides distensibility in response to hemodynamic stress, therefore helping the vessel to
maintain its shape. In contrast, collagen, the other major ECM component, provides tensile
strength and stiffness to the aorta. A set of experiments by Dobrin and colleagues demonstrated
the biophysical effects of elastin and collagen loss in an arterial tissue159. Under perfusion at
physiological pressures, arteries treated with elastase exhibited dilatation and stiffening,
whereas collagenase-treated arteries did not dilate but ruptured. Arteries treated with both
enzymes dilated rapidly and then ruptured. Given that the elastin in a structurally sound aorta
maintains vessel shape even under hypertensive conditions, its degradation appears to play a
key role in aneurysm growth. Collagen loss in aneurysms, which is typically not detected as
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early in aneurysm growth, appears to have a more important role in aneurysm rupture. This is
supported by the evidence that mutations in the gene for type III procollagen (COL3A1) lead to
the type IV form of the Ehlers-Danlos syndrome, the hallmark of which is a rupture of hollow
organs such as the aorta, uterus or bowel160.
Multiple studies examining MMP2 and MMP9 transcripts and activity have found them to
be increased in AAA tissue161-164. There is some variability in findings, and of the two, MMP9
has been more consistently identified as increased. Additionally, increased MMP9 activity may
be more specific to AAA as compared with MMP2162. Immunohistochemical analysis reveals
most MMP9 expression in AAA is derived from infiltrating macrophages, although evidence
exists for SMC production of MMP9163,165,166. Wilson and colleagues have also observed that
MMP9 levels are increased near the site of aneurysm rupture167. Several studies have shown
increased levels of MMP9 in the blood of AAA patients168,169, which are decreased following
surgical repair. These levels do not, however, have a strong predictive value for identifying the
presence of an aneurysm. In contrast to MMP9, MMP2 may have a more generalized role in
vascular inflammation. MMP2 expression is upregulated in aneurysms, particularly in small
ones. It is produced by both resident SMCs and macrophages, and can be found in normal
aorta as well as AOD tissue163. Increased MMP2 production and activation may therefore be a
tissue reaction to inflammation, as evidenced by the observation that SMC MMP2 production
increases in the presence of inflammatory cells163. Goodall and colleagues also reported that
MMP2 levels were increased in remote vasculature of AAA patients, suggesting that the
increase is part of a systemic response170.
In addition to ECM breakdown, MMP2 and MMP9 may also have roles in ECM signaling.
Johnson and colleagues showed that deficiency of both proteins led to decreased SMC invasion
in vitro171. Additionally, it was found that MMP9 may function in the interaction between SMCs
–/–

–/–

and ECM proteins since Mmp9 knockout mice (Mmp9 ), but not Mmp2

mice, had an impaired
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ability of SMCs to reorganize collagen171. Goodall and colleagues172 confirmed that MMP2 might
increase SMC migration by showing that SMCs from AAA patients have higher levels of MMP2
and increased invasiveness in vitro.
Several other MMPs have also been implicated in AAA pathogenesis. MMP12, also
known as metalloelastase, has been studied because of its ability to degrade elastin.
Comparison of AAA and control tissue has shown that MMP12 concentration is increased in
AAA tissue, particularly in macrophages and in association with elastin fibers173,174. MMP8, a
collagenase, is found at the site of aneurysm rupture, which is consistent with the hypothesis
that collagen breakdown is a necessary condition for AAA rupture. Two MMPs involved in
activation of other MMPs, namely MMP3 and MMP14, are also present in AAA tissue. MMP3 is
a known activator of MMP9 and is increased in AAA compared with AOD175,176. In contrast,
MMP14, which is also increased in AAA tissue, is known to activate MMP2 and colocalizes with
it in AAA tissue173,177. Finally, there are more recently discovered MMPs that have yet to be
evaluated in AAA tissue.
In addition to the MMPs, there is evidence of other families of proteases functioning in
AAA tissue. For instance, plasmin (PLG), a known activator of MMP3, has been found in AAA
tissue122,176. Of particular interest are cathepsins, a family of cysteine proteases that also have
the ability to degrade elastin fibers. Immunohistochemistry has identified cathepsins S, K and L
in the atheroma and intima of AAA tissue178,179. Similar to MMPs, the cathepsins were found in
macrophages and SMCs exposed to inflammatory stimuli, such as interferon gamma (IFNG)
and interleukin-1 beta (IL1B)178,179. Additionally, as with MMPs, cathepsins might have a role in
angiogenesis, as inhibition of cathepsin S reduced endothelial cell invasion in culture.
2.6.6 Oxidative Stress
Oxidative stress may also contribute to AAA pathogenesis. Reactive oxygen species
(ROS) and reactive nitrogen species (RNS) have been implicated in the pathology of several
conditions, such as Alzheimer’s disease and atherosclerosis180,181. Supporting a role for
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oxidative stress in AAA is the decreased expression of three enzymes responsible for
eliminating ROS, superoxide dismutase, glutathione peroxidase, and glutathione reductase, in
AAA tissue182. Simultaneously, inducible nitric oxide synthase shows increased expression.
Multiple cell types contribute to production of ROS and RNS in AAA tissue.
Macrophages in particular have NADPH oxidase and myeloperoxidase activity that can produce
–

large amounts of O2 and hypochlorous acid (HOCl), which in turn oxidize LDL and cause tissue
damage182. Angiotensin or TNF can stimulate SMCs to increase ROS production through
NADPH oxidase183. Not all sources are driven by inflammation, however, as SMCs can also
produce ROS in response to pulsatile forces182.
ROS and RNS could have several effects on aneurysm formation182. First, they could
induce cytokine production that then contributes to immune cell infiltration. Alternatively, they
can lead to activation of NFKB, an inflammatory transcription factor implicated in AAA. ROS can
also have an effect on the ECM through activation of MMP2 and MMP9. Finally, ROS could
possibly lead to SMC apoptosis, although this is debatable as ROS have been shown to
increase SMC proliferation.
2.6.7 Smooth Muscle Cell Apoptosis
The loss of SMCs via cytotoxicity-induced apoptosis may also lead to weakening of the
+

AAA wall. Although fewer in number than CD4+ T-cells, cytotoxic CD8 T-cells still represent a
significant proportion of lymphocytes in the aortic wall56,57. Similarly, NK and NKT cells comprise
a small number of lymphocytes by flow cytometry, but both cell types have been detected by
immunostaining in aneurysm tissue60, as have the apoptotic mediators perforin and Fas184.
When isolated from AAA plaques, NKT and CD4+ T-cells induce differential effects in vascular
SMCs, with the T-cells enhancing proliferation and NKT cells increasing apoptosis185.
Additionally, the number of peripheral blood NK cells is increased in AAA patients compared to
controls186.
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An important role for cytotoxic lymphocytes is further supported by microarray analysis.
Of the immune-related KEGG pathways identified by Lenk, et al., “Natural Killer Cell Mediated
Cytotoxicity” was the statistically most enriched pathway in AAA tissue compared to nonaneurysmal aorta tissue48. This pathway, which is not specific to NK cells, contains the cell
surface markers, downstream signaling genes and effector molecules that have been shown to
be involved in the activation and cytotoxic action of lymphocytes. Regardless of cell type
expressing these genes, the degree of enrichment suggests that cytotoxicity may be more
important in AAA tissue than previously thought. It is also possible that the effector molecules
have additional roles in AAA tissue. This is supported by a recent study that showed that
granzyme b (GZMB), a serine protease that can induce apoptosis in concert with perforin, has
the ability to degrade ECM proteins187. Additionally, TNF, an inflammatory cytokine upregulated
in this pathway, has been increasingly implicated in vascular disease188. Given these various
roles in AAA pathogenesis, genes in this pathway may be good targets for AAA therapies.
2.7 Hemodynamics and Site-Specificity of Aneurysm Formation
Despite our growing understanding of immunity and its role in AAA pathogenesis, the
mechanisms of the initial inflammatory infiltration in the aneurysm wall are not well understood.
The structure, hemodynamics and native cells of the aorta can all contribute to making the
tissue susceptible to aneurysm formation. For example, aortic SMCs display increased
polyploidy and gene expression with age189. The decreased susceptibility to AAA in women
indicates that sex hormones may alter biology of the aorta190, a hypothesis supported by work in
human tissues 191 as well as animal models192-195. SMC and endothelial gene expression is
altered by hemodynamic force196,197. Early phenotypic changes to SMCs in experimental AAA
further suggest that cells of the aorta may contribute to initiating an inflammatory response198.
2.7.1 Aortic Regional Variation and Disease Relevance
It is well established that vascular diseases, such as atherosclerosis and vasculitides,
display site-specific patterns of formation. Similarly, aneurysms usually develop in a limited
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number of blood vessels, including abdominal and thoracic aorta, intracranial vessels, and
popliteal arteries. There is some overlap in susceptibility to aneurysmal and atherosclerotic
disease, but not all vessels that are prone to atherosclerosis develop aneurysms, indicating that
factors specific to those vessels are important in aneurysm development122. Furthermore, the
abdominal aorta may be distinct even from other vessels that develop aneurysms; most AAA
patients are unlikely to present with a second aneurysm. AAA clusters into different families
than intracranial aneurysms (IA) and TAAD, suggesting that the abdominal aorta has
characteristics that differentiate it from other arteries, including other regions of the aorta.
Additionally, TAAD patients are much younger and there is a much smaller gender difference
(1.7:1 male-female ratio). TAADs also display different pathobiology, being characterized by
medial necrosis also known as “Erdheim’s cystic medial necrosis”, mucoid infiltration, and cyst
formation with elastin degradation and vascular smooth muscle apoptosis199. Finally, gene
expression in TAADs differs from AAA. An early cDNA array study by Absi et al.200 determined
the genes that are differentially expressed between thoracic aorta and TAAD and then
compared these with genes with altered expression in AAA. This analysis was able to show that
AAA is characterized by changes in genes related to inflammation whereas TAA is
characterized by changes in cell survival, proliferation and programmed cell death.
Structurally, the abdominal aorta displays characteristics that distinguish it from the
thoracic aorta. One key distinguishing feature is the number of elastic lamellae; approximately
40-80 elastic lamellae may be found in the thoracic aorta depending on location whereas the
abdominal aorta has approximately 30201. There is a corresponding decrease in elastin and
collagen per luminal surface area between the thoracic and abdominal regions50. In addition, the
ratio of elastin and collagen changes in the aneurysm susceptible infrarenal aorta, as there is
greater decrease in elastin content from the suprarenal to infrarenal aorta than in collagen
content. Another key difference is that relative to other species, the human abdominal aorta
deviates in the expected number of elastic lamellae. A study by Wolinsky and Glagov 201
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examining the elastic lamellae of thoracic and abdominal aortas in ten species observed that
human abdominal aorta had fewer elastic lamellae than would have been predicted by aortic
diameter or wall thickness. The most important consequence of this lack of elastic lamellae is
that human abdominal aorta lacks vasa vasorum. In a pattern consistent across species and
aortic segment, the innermost 29 lamellae constituted an avascular zone, receiving nutrient and
gas exchange by diffusion from the lumen, whereas vasa vasorum were present in additional
lamellae. Since the abdominal aorta would be predicted to contain more than 30 lamellae, and
therefore vasa vasorum, the outermost lamellae would be expected to experience relative
hypoxia. Furthermore, compared to other species with avascular aortas, the tension per lamellar
unit in the human abdominal aorta is much higher. Functionally, this may result in the outer
media of human abdominal aorta being more susceptible to stresses that lead to aneurysm
formation.
The blood flow through the abdominal aorta also displays characteristic patterns
associated with vascular injury. Due to its narrowing diameter and branch points, the blood flow
through the abdominal aorta creates regions of turbulent flow with decreased shear stress, or
blood flow directly over the endothelium. Vessels with turbulent flow are associated with
atherosclerosis formation, and the high prevalence of atherosclerosis in the abdominal aorta is
consistent with this observation. Further changes to the aortic geometry may increase the risk of
aneurysm formation. For instance, the geometry of the abdominal aorta may change with age,
altering hemodynamics22. On the other hand, allograft studies exchanging abdominal aorta with
thoracic aorta or pulmonary artery have demonstrated that the development of atherosclerosis
was dependent on the tissue of origin, not the vascular site.
Differences in embryological origin between the abdominal and thoracic aorta may
further explain the site-specificity of AAA (and TAAD)202. Le Lievre and colleagues showed that
the SMC lineages of the ascending thoracic and abdominal aorta differ, with origins in
neuroectoderm and mesenchyme, respectively51. Although similar, these two lineages showed
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an important difference in response to transforming growth factor beta (TGF-β; TGFB1)
signaling203, which has been implicated in the Marfan syndrome and TAAD111, perhaps
indicating a difference in media formation.
2.7.2 HOX Genes and the Vasculature
The abdominal aorta may also exhibit site-specific gene expression. One such group of
genes that shows spatial expression in the vasculature is the homeobox HOX family of
transcription factors. The common feature of the HOX genes is the homeodomain, a 61 aminoacid DNA-binding motif. There are a total of 38 HOX genes in four chromosomal loci (HOXA@,
HOXB@, HOXC@, and HOXD@). Each of these loci contains 9-11 genes that are divided into
13 paralogous groups. During development, HOX genes exhibit a unique temporospatial
expression pattern known as colinearity, where the 3’ HOX genes, or genes from lower number
paralogous groups such as HOXA1, HOXB1 or HOXB2, are expressed rostrally early in
development, with each more 5’ group being expressed progressively later and more caudally.
In adult tissues, HOX gene expression continues in spatially dependent manner, suggesting a
role in maintaining tissue identity. Microarray analyses of SMCs204, fibroblasts205-207 and bone
progenitor cells208 have shown that a cell’s tissue of origin can be identified by its specific HOX
gene profile. The HOX gene expression profile appears to be intrinsic to the cells rather than a
consequence of external factors, as expression of HOX genes in fibroblasts was not altered by
either 35 passages in vitro or by coculturing cells with differing HOX gene expression207. Using
Hoxa3- and Hoxc11-lacZ transgenic mice, Pruett and colleagues209 showed that the embryonic
expression pattern of Hoxc11 and Hoxa3 is maintained in the vasculature until at least 1 year.
Since they can directly affect the expression of many genes and pathways, transcription
factors such as the HOX genes are useful for studying in complex diseases such as AAA. The
importance of transcriptional networks in AAA is illustrated by a recent study examining
transcription factor binding sites in genes that are upregulated in AAA tissue. Binding sites for
nuclear factor kappa B (NFKB) and 7 transcription factors from the v-ets erythroblastosis virus
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E26 oncogene homolog (ETS) family were identified as overrepresented among the upregulated
genes. These results were consistent with previous studies showing that decoy oligonucleotides
against ETS1 and NFKB inhibit210 and reverse211 aneurysm progression in animal models.
Although the vascular functions of HOX genes are not fully understood, they can regulate
angiogenesis212,213, respond to inflammatory stimuli214,215 and target several genes relevant to
AAA, including MMPs216, NOS3217, and SPP1218-220.
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CHAPTER 3 – MATERIALS AND METHODS

3.1 Human Research Compliance
The experiments described herein, including collection and use of human tissue
samples, were conducted with the approval of the Institutional Review Board of Wayne State
University, Detroit, Michigan, and the research was carried out in compliance with the Helsinki
Declaration.
3.2 Genetic Association and Sequencing of Functional Positional Candidate Genes
3.2.1 Human Samples for Genotyping and Sequencing
Peripheral blood or skin fibroblasts were obtained for isolation of genomic DNA or RNA,
respectively, from AAA cases, relatives of AAA patients from multiplex families, and unaffected
controls. AAA cases used in genotyping (n = 487; 79% male) were collected at the University of
Pittsburgh (n = 103), the University of Liege in Liege, Belgium (n = 178), or Dalhousie University
Hospital in Nova Scotia, Canada (n = 206). Control samples (n=424) were spouses or patients
at the same hospital and were collected from Belgian (n = 269) and Canadian (n = 155)
populations at the latter two collection sites. Genomic DNA or RNA samples representing
familial AAA cases, sporadic AAA cases and unaffected controls were used in sequencing of
candidate genes (Tables 4 and 5).
3.2.2 DNA Isolation and Whole Genome Amplification
Genomic DNA used in genotyping and sequencing was isolated from peripheral blood as
previously described221. Genomic DNA was amplified by strand displacement amplication222 with
Phi29 polymerase using the Genomiphi Kit from Amersham (GE Healthcare Biosciences,
Piscataway, NJ). One microliter (10ng) of sample DNA was combined with 9 µl of sample buffer
according to kit instructions, heat denatured, and mixed with 1 µl of polymerase diluted in 9 µl of
reaction buffer. Amplification was carried out in thermal cycler for 17 hours at 30°C, followed by
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10 minutes at 65°C and cooling to 4°C. Dilutions of 1:5 and 1:100 were prepared for storage at 80°C and for use in polymerase chain reactions (PCR), respectively.
3.2.3 RNA Isolation and cDNA Synthesis
RNA was isolated from skin fibroblasts as previously described73. cDNAs were prepared
from RNA samples using SuperScript III First-Strand Synthesis Supermix from Invitrogen. Two
microliters of RNA diluted to 0.5 µg/µl was added to 10 µl 2X RT reaction mix, 2 µl RT enzyme,
and 6 µl diethylpyrocarbonate (DEPC) treated water. Samples were incubated at 25°C for 10
minutes, followed by 30 minutes at 50°C and reaction termination at 85°C for five minutes.
Residual RNA was eliminated by addition of 1 µl RNAse H for 20 minutes at 37°C.
3.2.4 Genetic Association Study
Genes surrounding the linkage peaks on chromosomes 4 and 19 were functionally
prioritized based on GO45 and KEGG46 annotations and by using expression data from a
previously described mRNA expression profiling of AAA and control abdominal aortic tissues48.
SNPs from the regions in and surrounding the candidate genes were tested for evidence of
association in order to determine which, if any, to evaluate by gene sequencing. Provided
sufficient LD between the marker SNP and the risk allele, power calculations using the Genetic
Power Calculator223 (http://pngu.mgh.harvard.edu/~purcell/gpc/) show sufficient power to detect
association (Table 3). SNPs were genotyped using the Illumina GoldenGate assay224 and the
call rate of each SNP was evaluated using the Gencall Software (version 6.1.3.28) from
Illumina. Deviation from Hardy-Weinberg equilibrium (HWE) was tested using an exact test225 as
implemented in Haploview226. Allelic association was tested using Chi-squared-test with one
degree of freedom (DF). To assess the potential for population stratification, HWE and allelic
association were also tested separately in the Belgian and Canadian subpopulations. Logistic
regression using Wald and likelihood ratio test (LRT) statistics as implemented in the ASSOC
program in Statistical Analysis for Genetic Epidemiology (SAGE) software was performed as an
additional test of association. Haplotype association was analyzed using a score test227
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implemented using the haplo.score function in the package haplo.stats using the R statistical
package228. In genes with evidence of association, the LD structure was examined using LD
plots generated in HaploView software using SNP genotype data obtained from the HapMap229
CEU (Caucasian) population.
3.2.5 Sequencing of Functional Positional Candidate Genes
Primer pairs specific for the coding sequence of CEBPG, cDNA sequence of PEPD, and
exonic sequences of CD22 were designed using PrimerQuestSM, a primer design tool based on
Primer3

software230

available

on

the

Integrated

(http://www.idtdna.com/Scitools/Applications/Primerquest/)

DNA

Technologies

(Integrated

DNA

website

Technologies,

Coralville, IA). Predicted melting points, primer hairpins and primer-dimer interactions calculated
using the SciTools programs in PrimerQuestSM were used in primer selection. One hundred
microliter volume PCR reactions were set up for sequencing using the following proportions: 10
µl 10x Buffer II (500 mM potassium chloride and 100 mM Tris-HCl, pH 8.3) (Applied Biosystems
Inc, Foster City, CA), 25 mM MgCl2 to desired final concentration, 0.8 µl of 25 µM
deoxynucleoside triphosphates (dNTP), 1.67 µl each of forward and reverse primers diluted to
10 µM, either 10 µl amplified genomic DNA or 5 µl cDNA, 0.5 µl (2.5 units) of AmpliTaq Gold
enzyme (Applied Biosystems), and nuclease-free water to the final volume of 100 µl. Reactions
were prepared on ice and kept chilled until immediate transfer to a thermal cycler heated to
>90°C. A standard program of 94°C for 10 minutes, followed by 40 cycles of denaturation
(94°C), annealing (variable) and elongation (72°C), and 3-minute incubation at 72°C was used.
Detailed cycle times and annealing temperatures are found in Table 6.
PCR products were diluted with a glycerol-bromophenol blue loading buffer and loaded
onto Tris-borate ethylenediaminetetraacetic acid (TBE) agarose gels. Lambda DNA-BstE II
Digest or 100 bp ladder from New England Biolabs (Ipswich, MA) were used to assess product
molecular weight depending upon predicted product size. PCR products with single clear bands
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(Figure 3) of the correct molecular weight were purified for DNA sequencing using Montage™
PCR purification columns (Millipore, Billerica, MA).
DNA sequencing was performed using the Sanger method231 on purified PCR products
at the Applied Genomics Technology Center (AGTC) at Wayne State University. Samples and
primers (Table 7) were diluted according to AGTC instructions. Polymorphisms were identified
by

alignment

of

sequences

using

BioX

software

(available

at

https://www.lagercrantz.name/projects/biox) and manual examination of the sequence plots.
3.2.6 Functional Analysis of Sequence Variants
To assess the potential function of identified sequence variants, in silico functional
analyses were carried. The freely available web program SIFT232 (Sorting Intolerant from
Tolerant) was used to predict the structural effects of non-synonymous substitutions. NetPhos233
was used to predict the creation or destruction of phosphorylation sites. To assess the potential
effect of 3’ untranslated region (UTR) sequence variants on microRNA binding, predicted
microRNA binding sites were obtained from the MicroCosm Targets Database234,235
(http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/).
3.3 Microarray Expression Profiling
3.3.1 Baboon Tissue Samples for mRNA Expression Profiling
Aortas from adult baboons (Papio hamadryas anubis) (n = 3) were obtained at necropsy
from animals at the Southwest National Primate Research Center, San Antonio, Texas (Table
8). The aortas were divided into 10-12 segments, placed in RNAlater solution (Ambion Inc.,
Austin, Texas) and shipped to Wayne State University. Upon arrival, samples were dissected
and, in order to ensure comparability between individuals, aortic sections were designated
numbers 1-12 using the aortic arch, renal arteries and iliac bifurcation as landmarks (Figure 4).
Sections from two baboons were also placed in 10% buffered formalin solution for fixation and
paraffin embedding.
3.3.2 RNA Isolation and Quality Control

45
Total RNA isolation was performed by extraction with guanidinium isothiocyanate and
centrifugation through a cesium chloride gradient236. Aortic tissue was stripped of adventitia,
minced using a scalpel in a Petri dish (Figure 5) and then homogenized with a rotor-stator
homogenizer (PRO Scientific Inc., Oxford, CT) in the presence of 4 M guanidinium
isothiocyanate, 0.1 M mercaptoethanol, 0.5% sarkosyl in 5 mM sodium citrate (pH 7). Solid
cesium chloride was added to the samples (final concentration 2.16 M), which were then
layered onto a cushion of 5.7 M cesium chloride in 0.1 M ethylenediaminetetraacetic acid
(EDTA). The samples were centrifuged in an ultracentrifuge using a Ti 60.4 rotor (Beckman
Coulter, Inc., Fullerton, CA) at 41,000 rpm for 18 hours at 20°C. RNA pellets were extracted with
chloroform:isoamyl alcohol and the RNA precipitated in ethanol with glycogen as a carrier. The
RNA was resuspended in RNA Storage Solution (Ambion Inc., Austin, TX) containing RNasin

®

(Promega Corp, Madison, WI).
In order to assess the quality of RNA used for expression profiling, the concentration and
RNA integrity of each sample was assessed. RNA concentration was measured using a
NanoDrop spectrophotometer (Nanodrop products, Wilmington, DE). An independent measure
of concentration and RNA integrity was obtained using separation by capillary electrophoresis in
an Agilent BioAnalyzer (Agilent Technologies, Inc. Palo Alto, CA). The RNA integrity number
(RIN), which measures RNA quality by evaluating ratio of the 28S ribosomal RNA (rRNA) and
18S rRNA, was determined for each sample in order to ensure sufficient quality for analysis with
Illumina arrays. RNA quality information is summarized in Table 8.
3.3.3 Microarray Analysis
Following the protocol from Illumina, 500 ng of total RNA (based on Nanodrop
measurement) was reverse transcribed and 1.5 µg of cRNA was hybridized to either Sentrix
Human WG-6 version 1 (n = 1) or HumanRef-8 version 2 microarrays (n = 2). The HumanRef-8
contains 22,184 probes for NCBI RefSeq genes and the Sentrix Human WG-6 contains 47,296
probes for both RefSeq genes and predicted genes from the UniGene database. Detection of
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genes was assessed in Illumina GenomeStudio (formerly BeadStudio) software. Each array
contains ~30 replicates for each probe sequence; comparison of the distribution of fluorescence
signals from a probe of interest with the distribution obtained from negative control probes
allows for a “Detection Score” (1 - detection p-value) to be calculated. Probes with a detection
score of “0.99” in at least one sample were considered detected for further analysis.
Quality control (QC) measures were undertaken to ensure microarray performance.
Systematic bias was analyzed by examination of raw expression data histograms (data not
shown) and principle components analysis (PCA) (Figure 6). Additionally, to ensure that the
Illumina probe sequences directed against a single validated gene, Basic Local Alignment
Search Tool (BLAST) analysis was performed on each sequence, yielding 21,506 and 20,518
probes from the Sentrix Human WG-6 and HumanRef-8 platforms, respectively. Probes were
assigned updated accession numbers and aligned to exons using Perl scripts. Due to probe
sequence changes made between array versions 1 and 2, probes were mapped between
platforms using probe sequence, accession number, and exon as criteria.
In order to identify genes with relative increases or decreases in expression along the
length of the aorta, linear regression was performed using the R statistical package. Confidence
intervals (CI) (99%) were constructed for the calculated slope and those probes with a CI not
crossing zero were considered to have increasing or decreasing expression.
3.4 Protein Analyses
3.4.1 Tissue Samples Used in Protein Expression Studies
Control non-aneurysmal aortas (n = 24) were obtained post-mortem at autopsy from the
local medical examiner in Detroit, Michigan (Table 9). Exclusion criteria were known malignancy
or systemic infection. Tissue was dissected and transported to Wayne State University in chilled
saline. The adventitial layer was stripped and the tissue dissected into pieces for protein
analyses. Dissected samples were fixed in 10% buffered formalin, embedded in Tissue Tek®
Optimal Cutting Temperature (O.C.T.) media (Sakura-Finetek USA, Inc., Torrance, CA) using
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plastic cryomolds and frozen over dry ice, or flash-frozen in liquid nitrogen. Formalin-fixed
samples were embedded in paraffin molds for sectioning after at least 24-hours fixation. Flashfrozen and OCT-embedded tissues were stored at -80°C until further use.
AAA tissue was trimmed from the aneurysmal sac as part of elective surgical repair by
vascular surgeons (Table 10). Tissue samples were removed solely for the purpose of graft
placement and would otherwise be discarded. Samples were fixed in formalin solution and then
embedded in paraffin molds.
3.4.2 Preparation of Protein Homogenates
Between 200 and 400 mg of flash-frozen aortic tissue was weighed in polypropylene
tubes chilled to -80°C. Three ml of 4°C homogenization buffer consisting of 50 mM
tris(hydroxymethyl)aminomethane (Tris), pH 7.4, 100 mM sodium chloride, 5 mM EDTA, 5 mM
ethylene glycol tetraacetic acid, 1% Triton X-100, 0.1% sodium dodecyl sulfate (SDS), 1x
Mammalian Protease Inhibitor Cocktail (Catalog Number P8340, Sigma-Aldrich, St. Louis, MO)
was added to each tube immediately prior to homogenization. Additionally, either 1x HALT
Phosphatase Inhibitor (Fisher Scientific, Pittsburgh, PA) or Phosphatase Inhibitor Cocktail II
(Sigma-Aldrich, St. Louis, MO) was included in the homogenization buffer formulation for a
majority of samples. Samples were homogenized in a biosafety cabinet with tubes resting in an
ice bath using a chilled rotor-stator homogenizer (PRO Scientific Inc., Oxford, CT) for 2x10
seconds. Residual solution was rinsed from the homogenizer using an additional 1 ml of
homogenization buffer. Homogenized samples were centrifuged at ~15,000 g for at least 10
minutes, the remaining supernatants were transferred to clean tubes and the pellets discarded.
Protein homogenate concentration was determined using the biochinic acid (BCA) assay
from Pierce following the manufacturer’s instructions (Thermo Fisher Scientific, Inc., Rockford,
IL). Homogenates were diluted either 1:2 or 1:6 in tris-buffered sodium chloride (TBS), pH 7.4.
Fifty microliters of diluted sample were added to 1 ml of BCA working reagent and incubated at
37°C for 30 minutes. A standard curve was prepared according to the manufacturer’s
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instructions using bovine serum albumin (BSA). Samples were transferred to 1 ml disposable
cuvettes and absorbance at 562 nm was read using a BioPhotometer spectrophotometer
(Eppendorf North America, Hauppauge, NY). Sample concentration was determined by
averaging the concentrations determined by 1:2 and 1:6 dilutions.
To check for protein degradation, samples were electrophoresed under denaturing
conditions on polyacrylamide gels. Samples were diluted to a concentration 0.25 µg/µl in a
solution of 62.5 mM Tris, pH 6.8, 10% glycerol, 4.1% SDS, 0.1 M dithiothreitol (DTT) and
0.0005% bromophenol blue. Twenty-microliters of diluted samples were denatured at 100°C for
5 minutes and loaded onto precast 12% polyacrylamide gels (8.6 x 6.8 cm) from Bio-Rad (BioRad Laboratories, Hercules, CA). Ten microliters of Novex Sharp Prestained Protein Standard
®

was loaded to one lane (Invitrogen Corporation, Carlsbad, CA). Gels were electrophoresed at
29 volts/cm in a Bio-Rad electrophoresis cell for approximately 35 minutes. Gels were then fixed
and stained using a Rapid Coomassie protocol237. Gels were fixed for 30 minutes in 25%
isopropanol, 10% acetic acid solution followed by staining for at least 2 hours in 0.006%
Coomassie brilliant blue 250, 10% acetic acid solution. Finally, gels were destained in 10%
acetic acid and examined for protein degradation (Figure 7). Following assessment of protein
concentration and integrity, homogenates were aliquotted into 1.5 ml microcentrifuge tubes and
placed at -20°C for use in western blotting or at -80°C for long-term storage.
3.4.3 Western blotting
Samples were diluted in a solution 58.3 mM Tris, pH 6.8, 5% glycerol, 1.71% SDS, 0.1
M DTT, and 0.0002% bromophenol blue and denatured for 5 minutes at 100°C. Dilutions were
made so that antibody dependent amounts of protein (20 µg for HOXA4 and ACTB; 0.5 µg for
ACTA2) would be present in a 30 µl load. Samples were loaded onto precast 4-15% gradient
polyacrylamide gels (Bio-Rad Laboratories, Hercules, CA). Five microliters of Novex Sharp
®

Prestained Protein Standard were loaded into one lane. Samples were electrophoresed for
approximately 35 minutes at 200 volts in a Bio-Rad electrophoresis cell. Gels were allowed to
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equilibrate in chilled transfer buffer consisting of 20% methanol, 0.19 M glycine, and 25 mM Tris
for 15 minutes. Proteins were then transferred to nitrocellulose membranes in chilled transfer
buffer in a Bio-Rad Mini Trans-Blot Cell (Bio-Rad Laboratories, Hercules, California) at 100 volts
for 1 hour. After protein transfer, blots were fixed at room temperature for 15 minutes in 25%
isopropanol, 10% acetic acid, rinsed briefly with 0.1 M Tris, pH 7.5, 0.154 M sodium chloride
with 0.1% Tween 20 (TBS-Tween or TBST) and blocked for 45 minutes at room temperature in
5% skim milk in TBST. Blots were then transferred to heat-sealable bags and incubated
overnight at 4°C with primary antibody diluted in blocking solution. Primary antibodies are
described in Table 11. Following incubation, blots were washed three times for 10 minutes in
TBST and incubated for 30 minutes at room temperature followed by 30 minutes at 4°C with
HRP-conjugated

IgG

preabsorbed

species-specific

secondary

antibody

(Santa

Cruz

Biotechnology, Inc., Santa Cruz, CA, product number sc-2054 and GE Healthcare Biosciences,
Piscataway, NJ, product number NXA931) diluted to 1:25,000 in TBST containing 4% serum of
the secondary antibody species.
Following a final washing in TBST, blots were visualized using Pierce SuperSignal West
Pico enhanced chemiluminescent substrate according to manufacturer instructions Blot
visualization was done using a Bio-Rad ChemiDoc Imaging system. Autoradiography film
exposures were also obtained for each blot using either Kodak X-OMAT LS (Eastman Kodak
Company, Rochester, NY) or Genemate Blue Lite (ISC Bioexpress, Kaysville, UT) film.
3.4.4 Blot Quantification and Statistical Analysis
Quantification of blot density was done using Quantity One® software from Bio-Rad. An
intensity-per-area value was obtained for each sample band as well as for a control band loaded
on all blots. Band intensities were adjusted between blots using control band intensities.
Intensity values adjusted for expression of either smooth muscle actin or beta actin were then
calculated. Actin-adjusted band intensity values were input into the R statistical package. A
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Wilcoxon signed rank test was used as a test statistic to compare the intensity values of protein
bands from thoracic and abdominal aortic wall samples.
3.4.5 Immunohistochemistry
Immunohistochemistry of O.C.T-embedded frozen tissue (Table 9) was performed using
the VECTASTAIN Elite Avidin:Biotinylated enzyme Complex (ABC) Kit (Vectorlabs, Burlingame,
CA). Air-dried slides containing eight-micrometer sections were fixed in methanol containing 3%
hydrogen peroxide to quench endogenous peroxidases and then blocked with serum for 20
minutes.

Treatment

with

primary

antibody,

secondary

antibody,

ABC

reagent,

and

diaminobenzadine substrate were performed following manufacturer instructions. Each
treatment was preceded by a 10 minute PBS wash. Immunostained slides were counterstained
with hematoxylin and mounted with a coverslip. The primary antibodies used are described in
Table 11.
In some instances, immunostaining was carried out using 5 µm sections of formalinfixed, paraffin-embedded (FFPE) aortic tissue (Tables 9 and 10). Sections of human tonsil
(CD22), human kidney (PEPD) or tissue array containing nine human tissues including kidney
clear cell carcinoma, malignant melanoma and breast tissue (HOXA4) were used as positive
controls. Sections were deparaffinized in a dry oven, rehydrated using sequential rinses in
Histoclear xylene substitute (National Diagnostics U.S.A., Atlanta, GA), 100% ethanol, 95%
ethanol and water. Antigen retrieval was performed by microwave-treatment of slides.
Endogenous peroxidase was blocked by placing slides in 3% methanol/peroxide block solution
for 10 min. The slides were incubated with primary antibody or with serum derived from an
unimmunized animal of the same species as the primary antibody as a negative control using
an automatic immunostainer (Autostainer, DAKO, Carpinteria, CA). A secondary antibody with
avidin-biotin peroxidase amplification from DAKO was used and the signal detected using
diaminobenzidine as a chromogen. Images were obtained using either a Leica DM4000B (Leica
Microsystems, Inc., Bannockburn, IL) or Nikon (Nikon Instruments Inc., Melville, NY)
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microscope using objectives ranging from 4x to 40x. Images were digitally captured with either
Leica Imaging Suite or Nikon ACT-1 software. Exposure settings for Leica microscope were
preset238, and for the Nikon microscope were set to 1/300, 1/200, 100 and 1/25 second for the
4x, 10x, 20x and 40x objectives, respectively.
3.4.6 Cell Culture and Immunofluorescence
Human aortic smooth muscle (catalog number 6110 from ScienCell Research
Laboratories; and catalog number CRL-1999 from American Type Culture Collection,
Manassas, VA) and endothelial cells (catalog number 6100 from ScienCell Research
Laboratories, Carlsbad, CA; and catalog number C-12271 from PromoCell, Heidelberg,
Germany) were grown on 2-well Permanox chamber slides (Lab-Tek, Thermo Fisher Scientific,
Rochester, NY). Cells were fixed with 3% paraformaldehyde and permeabilized with 0.05%
Triton X-100 in PBS, and then incubated with rhodamine-phalloidin (Molecular Probes,
Invitrogen Corporation, Carlsbad, CA) at 1:100 dilution, and anti-HOXA4 with 1:200 dilution
(ab26097, Abcam Inc., Cambridge, MA), followed by incubation with fluorescein-conjugated
affinity-purified donkey anti-rabbit IgG (1:100 dilution in BLOTTO; Jackson ImmunoResearch
Laboratories Inc., West Grove, PA). The stained cells were examined using a Zeiss Observer
Z1 inverted light microscope equipped for epifluorescence.
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CHAPTER 4 – RESULTS
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4.1 Identification of Potential Risk Alleles in Functional Positional Candidate Genes
4.1.1 Selection of Functional Candidate Genes
The AAA1 and AAA2 linkage intervals together contain over 100 genes. Since it would
be prohibitively expensive to conduct deep sequencing on each of these genes to identify
potential risk variants, functional positional candidate genes were identified using several
criteria. Gene ontology categories and KEGG pathway membership for each gene in the region
of each linkage peak were examined and ten genes were identified with annotated functions
directly relevant to AAA pathogenesis (Table 12). Nine of these genes were selected based
upon an annotated function in the immune system, which was considered relevant to AAA given
the evidence for AAA as an immune-mediated disease. An additional functional candidate,
peptidase D (PEPD), was chosen based upon its role in collagen metabolism.
Gene expression for each candidate was assessed using microarray expression profiles
of AAA and control aortic tissue. The expression data were previously generated in our
laboratory and the study design has been described in detail48. Utilizing expression data in
functional prioritization has been described in the literature239,240 and by our laboratory44, but
since all of the functional candidates identified by annotation were expressed in either AAA or
control abdominal aorta, none were excluded by this criterion. It was noted, however, that four
of these genes, CEBPA, NFKBID, HCST and TYROBP, were significantly upregulated in AAA
tissue and that an additional gene, CD22, was expressed only in AAA tissue.
4.1.2 Candidate Gene Association Study
Sixty-six SNPs were genotyped in or around the ten functional candidate genes found
within the AAA1 and AAA2 linkage loci. Eleven SNPs were excluded from further analysis
based upon low genotype call rates. SNPs were also tested for evidence of deviation from
HWE. As HWE disequilibrium can result from underlying biases, such as population structure, or
from genetic association, HWE was assessed in the two major populations studied, Belgian and
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Canadian, as well as in conjunction with evidence of association. Four SNPs showed deviation
from HWE in the absence of evidence of association, and were excluded from further analysis.
Using an allelic χ2 test of association, eight SNPs in three genes, CD22 (2 SNPs),
PEPD (5 SNPs), and HAMP (1 SNP), were identified as being nominally associated with AAA (p
< 0.05). When tested for genotypic association using logistic regression, six of these SNPs were
nominally associated, two were not associated and an additional SNP in GPI was identified.
Although not significantly associated, SNPs in NFKBID and IL15 did approach nominal
significance (p < 0.10) by this test. Since there were multiple associated SNPs in PEPD, the LD
structure of the genotyped SNPs was examined using an LD plot of genotype data from the
HapMap project CEU Caucasian population (Figure 8). Both the genotyped SNPs and additional
validated SNPs in the region of CD22 were also examined with an LD plot to examine haplotype
structure (Figure 9).
In order to identify population-specific effects, allelic association was evaluated in the
Canadian and Belgian subpopulations separately. For a majority of the SNPs identified above,
evidence of association was stronger in the Canadian subpopulation. Four SNPs (rs756796,
rs889140,

rs7248389,

and rs7251432)

were

nominally

associated in the

Canadian

subpopulation alone, but only one of these (rs7248389) showed evidence of association in the
Belgian subpopulation. It is notable that for the two most significantly associated SNPs in PEPD,
each was either nominally associated or approaching nominal association in both
subpopulations. Additionally, for each of the two associated SNPs in CD22, it appeared that
association results were driven by a different subpopulation. Finally, two associated SNPs
located in PEPD (rs889140 and rs7248389) did show deviation from HWE driven by the Belgian
controls, but were not excluded due to evidence of association in the Canadian subpopulation.
All nominally associated SNPs and their p-values for the different tests are summarized in Table
13.
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Haplotypic tests of association were also performed on SNPs in CD22 and PEPD. Using
a sliding window of five consecutive SNPs, nominally significant haplotypic association (p =
0.0026) was identified in the region of PEPD at the SNPs rs10500265-rs6510383-rs7248389rs7250833-rs2241380. Nominally significant haplotypic association (p = 0.0065) was also
identified in two SNPs in CD22 (rs756796-rs2267574).
4.1.3 DNA Sequencing of Exons in Candidate Genes with Putative Association
Sequence analysis is a commonly employed method to identify novel mutations in
genomic regions with evidence of genetic linkage or association. Three genes, CD22, CEBPG,
and PEPD, were chosen for DNA sequencing based upon several criteria, including functional
plausibility, evidence of association and, in the case of CD22, expression in AAA tissue only. No
significant SNPs were detected within CEBPG, but it was chosen for sequencing since it is in
close proximity to PEPD and could plausibly contribute to the association signal detected in that
gene. CD22 was also considered an intriguing candidate gene since it is only expressed in AAA
tissue.

Protein

expression

of

CD22

and

PEPD

in

the

aorta

was

confirmed

by

immunohistochemical staining of paraffin-embedded tissue sections of AAA and control
abdominal aorta (Figure 10).
Exons were sequenced from each gene covering a minimum of the protein coding region
of each gene since the functional changes associated with exon sequence changes are often
easier to predict than with intronic sequences. Furthermore, the number of sequencing reactions
necessary to cover the large intronic regions of CD22 and PEPD was cost-prohibitive.
The protein-coding region of CEPBG was sequenced from the genomic DNA of 22 AAA
cases, 11 familial and 11 sporadic, and two controls. CEBPG does have a large 3’ UTR that we
chose not to sequence based upon the relatively weak evidence for association within the gene.
No sequence variants were identified within the regions sequenced and therefore no further
analysis was pursued with this gene
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PEPD contains 15 small exons that are spaced over a large genomic distance, so we
opted to sequence cDNA since the spliced transcript could be covered in only three PCR
reactions. Seven sequence variants were identified in PEPD from AAA cases and one control
(Tables 14 and 15; Figure 11A). Three of the sequence variants identified were novel, in that
they were not in either the NCBI SNP or Celera databases. Two SNPs coded for nonsynonymous amino acid changes: rs17570, which results in a leucine to phenylalanine
substitution at amino acid for 435, and a novel variant resulting in an alanine to threonine
substitution at amino acid 432.
Although also consisting of 15 exons, CD22 was sequenced from genomic DNA due to
the larger transcript size and closer exon spacing that allowed for coverage of multiple exons
with a single reaction. A total of 20 sequence variants were identified, including five novel
variants (Tables 16 and 17; Figure 11B). Five variants were in the protein-coding region,
including two coding for non-synonymous amino acid substitutions, and six were found within
the 3’ UTR.
4.1.4 Predicted Functional Changes
Several in silico analyses were used to predict whether any of the observed sequence
changes might alter protein function or regulation of gene expression. To assess the potential
effect of non-synonymous amino acid substitutions, each sequence variant was analyzed with
the SIFT web application, which predicts whether amino acid changes that will not be tolerated.
SIFT predicted that all four amino acid substitutions coded by the sequence variants that we
identified in CD22 and PEPD would be tolerated. Structural modeling of PEPD demonstrated
that the identified amino acid substitutions A432T and L435F, resided in close proximity in a
region that appeared to tolerate structural changes (Figure 12)
The 3’ UTR of many genes acts as a binding site for microRNAs (miRNAs) in posttranscriptional gene regulation241. In order to see if any of the sequence variants identified in the
3’ UTR of CD22 might interrupt miRNA binding, predicted miRNA binding sites were obtained
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from MicroCosm database hosted by EMBL-EBI. Binding site predictions for four miRNAs did
overlap with two sequence variants (Figure 13). Only one binding site prediction had a perfect
complementarity in the miRNA seed region (base pairs 2-7) and potential base pairing was not
altered by the sequence change. One SNP (rs73031792) was located in the seed region of two
predicted binding sites, but since neither prediction had perfect seed region complementarity,
they were not pursued further.
4.2 Regional Gene Expression in the Aorta
4.2.1 Whole-Genome Expression Profiling of Full-Length Baboon Aortas
To identify novel candidate genes with spatial expression changes reflective of aortic
heterogeneity, whole genome expression profiling was undertaken using tissue from the entire
descending aorta. As no full-length human aortas were available at the time of analysis, aortas
from baboons (Papio hamadryas anubis) were used. The baboon has been successfully used
as a model for vascular disease242 and high quality samples could be obtained immediately
upon necropsy. Since no baboon-specific microarray platform was available at the time of
analysis, it was necessary to use human microarray platform. Previous reports have also
successfully used human microarrays to study primate gene expression243,244 and humans and
baboons have an ~96% homology in DNA sequence, so we were confident that we would have
sufficient genomic coverage to identify genes for further study. It is possible, however, that even
a single base pair change complementary to a microarray probe will lead to decreased binding
so an increase in false negatives was predicted. Illumina BeadArrays were selected for their
comprehensive genomic coverage, previous successful use by the laboratory48, and ability to
easily assess expression of a gene through calculation of the detection score based on
accepted signal detection theory.
Microarray analysis of the baboon tissue was conducted in two phases. An initial
microarray experiment was performed using Illumina Sentrix Human WG-6 arrays to assess the
feasibility of identifying genes with spatial expression patterns. Aortic samples from two
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additional baboons were later analyzed using Illumina HumanRef8 arrays. Since Illumina
updated its probesets between experiments, the two platforms were initially analyzed
separately. Both platforms performed well with respect to gene expression from the baboon. A
total of 8,748 probes were detected on the Sentrix Human WG-6 arrays, with a mean of 6,826
per aortic segment. On the HumanRef-8 arrays, 9,403 and 8,725 probes were detected for the
two baboons, with means of 7,428 and 7,220, respectively. This expression compared favorably
with the human expression. Comparing expression in baboon and human abdominal aorta
probed for using the Sentrix Human WG-6 platform, the baboon sample had 7,384 detected
probes compared with 12,881 probes detected in human aortas (mean = 10,218), reflecting the
expected increase in false negatives from using baboon samples on a human platform.
To identify genes with potential relevance to the regional nature of AAA, linear
regression analysis was carried out on the baboon data. The regional nature of aortic
aneurysms would suggest that genes with well-defined differences between abdominal and
thoracic aorta would be most informative. Nevertheless, if the true expression either increases
or decreases monotonically along the length of the aorta, linear regression will identify most of
the genes with these well-defined differences. Due to the differences between Illumina array
platforms, linear regression was performed separately for each platform, identifying 832
significant probes (99% CIs of the regression slope did not cross zero) in the baboon analyzed
on Sentrix Human WG-6 arrays (Baboon 1) and 86 significant probes from the combined data of
the baboons analyzed using the HumanRef-8 arrays (Baboons 2 and 3). Combining these data
identified 23 genes that showed lengthwise increase or decrease in expression in samples
taken from along the aorta that was consistent between both platforms (Table 18). Genes
showing the steepest slopes included transforming growth factor, beta-induced, 68 kDa
(TGFBI), allograft inflammatory factor 1-like (AIF1L), superoxide dismutase 1, soluble (SOD1)
and deafness, autosomal dominant 5 (DFNA5). Interestingly, three of the 23 genes belonged to
the homeobox (HOX) family of transcription factors (HOXA2, HOXA9, and HOXC6). Analysis of
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genes that were detected or probed for on only one platform identified 118 additional genes on
the WG-6 platform and 25 on the HumanRef-8 platform (data not shown), including two and
three additional HOX genes, respectively (HOXA10, HOXD8, HOXA4, HOXC8, and HOXC9).
Based upon these findings, expression of all 38 HOX genes was examined further. In addition to
the eight HOX genes identified by regression analysis, manual examination of expression
patterns identified HOXA5, HOXA7, HOXB4, HOXB7, and HOXC10 as having potential
expression trends (Figure 14).
4.2.2 HOX Gene Expression in AAA
Based upon our observation that the HOX genes exhibit regional expression changes,
we hypothesized that HOX gene expression might be altered in AAA. A previously performed
microarray-based comparison of mRNA expression levels in AAA and control abdominal aortic
tissues using the Sentrix Human WG-6 platform demonstrated expression of 17 HOX genes in
human abdominal aortic control tissue48, all of which except HOXA4 were detectable in baboon
abdominal aorta using the Sentrix WG-6 platform. An additional HOX gene, HOXA11, was
expressed in AAA tissue, but all 17 others had lower expression in AAA tissue, including ten
that were significantly decreased after correction for multiple testing (Figure 15).
4.2.3 HOXA4 Protein Expression in Human Aorta
Examination of the combined data on spatial and disease-related HOX gene expression
changes identified a subset of four genes, HOXA2, HOXA4, HOXC6 and HOXD8, which
exhibited both. As it was the most significantly decreased HOX gene in AAA tissue, HOXA4 was
chosen for further analysis. In order to confirm that HOXA4 is translated into protein and is
therefore relevant to vascular function and to offer morphological insight into expression of the
gene, immunohistochemical staining of aortic tissue was conducted using an antibody specific
for HOXA4. This antibody binds to HOXA4 on western blots as demonstrated by siRNA
knockdown245, but has not been tested for use in immunohistochemistry. Initial testing using a
tissue array showed staining of renal clear cell carcinoma, breast tissue and melanoma (data
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not shown). Negative control staining using a non-immune rabbit serum exhibited some light,
diffuse staining but with most areas devoid of stain (data not shown).
Since formalin fixation of tissue in conventional immunohistochemistry can result in
epitope crosslinking, immunohistochemistry of frozen sections was initially carried out. Using
cryosections of paired human thoracic and abdominal aortic tissue embedded in OCT media (n
= 6 pairs), staining was observed in the nuclei and perinuclear regions of several cell types
through all three layers of the aorta (Figure 16A). Intimal staining of endothelial cells and medial
staining of SMCs were both observed, with the outer half of the media staining more intensely in
several cases. Sparse staining was observed in the adventitia, especially surrounding
adventitial vessels. As preparation of the frozen sections lead to some disruption of cell
morphology, immunohistochemistry using FFPE tissue samples was also tested. Similar
staining patterns were observed with primarily nuclear and perinuclear staining (Figure 16A-B).
Several tissue sections also exhibited a more diffuse, punctate staining pattern in both frozen
and FFPE sections. Staining did not differ qualitatively between thoracic and abdominal aorta,
with staining observed in similar cell types and vessel layers (Figure 16 D-E).
Closer examination of the punctate staining pattern showed that it was only present in
tissues from adult donors and was particularly strong in elderly donor tissue (age > 50). In
contrast, tissue from the three adolescent donors exhibited a more localized staining pattern
around the nuclei. These age-related differences were present in both frozen and FFPE
sections. Consultation with a pathologist confirmed that the nuclear staining in the younger
samples was most likely specific, but that the diffuse staining in the older individuals was a
possible artifact due to reagent reactions to calcium deposits in the tissue. Potential age-related
differences were not quantitated, however, due to an insufficient number of adolescent samples
available for comparison.
To confirm the HOXA4 expression patterns observed in the baboon aortas, HOXA4
protein expression was assessed quantitatively by western blotting of paired human thoracic
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and abdominal tissue. In non-aneurysmal aortic tissue, HOXA4 was detected as a single band
running at ~33 kDa (Figure 18A). At the time of analysis, no full-length recombinant peptide or
expression lysate was available as a positive control, but the antibody did bind to the
immunizing peptide, (Figure 18B) and, as noted above, it has shown specificity on western blots
in siRNA knockdown experiments245. For quantification purposes, beta-actin was used as a
loading control (Figure 18C). Using 24 paired human thoracic and abdominal aortic tissue
samples, the beta-actin adjusted HOXA4 expression in the thoracic aorta was significantly
higher than in the abdominal aorta (p < 0.0001), which was consistent with the expression
pattern observed in the baboon microarray analysis (Figures 19 and 20A). Since the thoracic
aorta has a higher smooth muscle content than the abdominal aorta, smooth muscle alpha actin
levels were also investigated to determine whether the difference (Figure 18D) in HOXA4
expression was a result of differences in SMC density. After correction for alpha-actin content,
the expression differences between abdominal and thoracic aorta changed slightly but remained
significantly different (p < 0.001), an indication that SMC density might have a small effect on
HOXA4 expression but does not account for the main observation of spatial difference in
HOXA4 levels (Figures 19 and 20B).
The effect of age on HOXA4 expression was also investigated using western blot data.
Regression lines were generated for the human thoracic and abdominal aortic samples that
identified negative correlation between HOXA4 protein levels and age (Figure 21).
4.2.4 In Vitro Characterization of HOXA4 Protein
In order to further characterize the cellular localization of HOXA4 protein in the vascular
cells, immunofluorescent staining for HOXA4 was performed using cultured low-passage human
aortic endothelial cells (HAECs) and human aortic smooth muscle cells (HASMCs). Staining
was strongest in the perinuclear region, with some evidence of nuclear staining (Figure 22).
HOXA4 did not colocalize with filamentous actin, which stained using rhodamine-phalloidin. The
staining pattern observed was similar between the different cell types.
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CHAPTER 5 – DISCUSSION

5.1 Genetic Association and Sequencing of Functional Positional Candidate Genes
5.1.1 Identification of Candidate Genes in the AAA1 and AAA2 Linkage Intervals
This study utilized genetic association methods and exon sequencing to identify
sequence variants contributing to AAA risk. Strong evidence of linkage exists on chromosomes
4 and 19 in the AAA1 and AAA2 loci36,37, but there are several hundred genes within these two
regions combined, necessitating the use of additional methods to identify specific risk genes. To
do this, we functionally prioritized the genes in the regions surrounding the linkage peaks using
annotation databases and expression profiling of AAA and non-diseased control abdominal
aortic tissue. The freely available GO and KEGG databases allowed us to quickly identify ten
genes with annotated functions relevant to AAA pathogenesis, a number that was deemed more
manageable for further study. In contrast to previous association studies that have focused
genes specifically identified in AAA pathogenesis, our approach was not restricted to genes with
a known function in aneurysms. Rather, each gene we identified needed only to have a
plausible role in aneurysm etiology or pathogenesis. The genes identified ranged from clearly
relevant, such as IL15, a cytokine with diverse roles in the immune system including stimulation
of T-cell proliferation246 to more tangential, such as GPI, which normally functions in glycolysis,
but has autoantigenic properties247. One limitation of this approach was that poorly or
unannotated genes may have been missed. Alternative methods such as text-mining of
abstracts may have yielded a more complete list of functional candidate genes, but would have
likely been far more time consuming and may not have yielded much additional information.
Gene expression was also included as an additional functional criteria to prioritize
candidate genes44. Although it is acknowledged that there are plausible scenarios where a gene
that is expressed in a different tissue could alter disease risk, this was deemed less likely for a
highly regional disease like AAA. Since each of our functional candidate genes was expressed
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in either AAA or control abdominal aortic tissue, this criterion was not critical to this study.
Genes expressed significantly higher or only in AAA tissue, however, were of additional interest
from a functional standpoint.
5.1.2 Genetic Association Studies
Association testing of the functional positional candidate genes demonstrated nominal
association in four genes. Despite evidence of linkage, identification of nominally significant
SNPs was not expected due to the potential for allelic heterogeneity or rare variants. Evidence
of association in two of the candidate genes, PEPD and CD22, was of considerable interest.
PEPD and CD22 are particularly strong candidate genes for altering AAA risk, based on gene
function, association evidence, and gene expression. We have also shown that both genes are
present as protein in AAA tissue, indicating that they can plausibly affect disease pathogenesis.
PEPD, which is also known as prolidase, is an aminodipeptidase that cleaves di- and
tripeptides with C-terminal proline or hydroxyproline residues. It has a significant role in collagen
metabolism and dysregulation of its activity has been implicated in several diseases248. Loss of
PEPD activity from nonsense mutations results in a clinical syndrome of variable expressivity,
but may include skin lesions, mental retardation, facial malformations and recurring lung
infections248. Conversely, increased serum activity of PEPD has been associated with diseases
such as asthma249, CAD250, fatty liver disease251, and erectile dysfunction252. PEPD activity is
sensitive to doxycycline253, which is intriguing given the therapeutic potential of this drug in AAA.
CD22 is a sialic-acid binding protein found on cells of B-cell lineage. It can inhibit signaling
through the B-cell receptor254, suggesting that impairment of gene function might lead to
dysregulation of the immune response and either autoimmune disease or increased
inflammation. Supporting this hypothesis is evidence of a role for CD22 in systemic sclerosis
(SSc); anti-CD22 autoantibodies contribute to SSc pathogenesis255 and there is evidence of
association between a SNP in CD22 and SSc256. Cd22 knockout mice, however, display a
minimal phenotype with no evidence of increased autoimmune disease254. It is still plausible,
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however, that polymorphisms in CD22 might modulate the immune response in an inflammatory
disease such as AAA through changes in the amount or function of the gene.
Despite the presence of nominally associated SNPs, evidence of association was
weaker in HAMP and GPI and they were therefore not selected for sequencing. Both genes had
only one nominally associated SNP in the region of the gene; evidence of association in
additional SNPs would make a stronger case for possible risk modification in AAA. The currently
known functions of HAMP and GPI also make them less compelling, although still plausible,
candidate genes for AAA. As previously mentioned, GPI primarily acts an enzyme in glycolysis
and gluconeogenesis but has also been described as an autoantigen in rheumatoid arthritis
(RA)247. This is intriguing given the hypothesis that AAA also has an autoimmune component,
but a connection between the diseases is not supported by either RA or AAA epidemiology.
Inflammatory AAA has been associated with autoimmune disease and there are rare cases of
rheumatoid aortitis257, but there have been no observations concerning phenotypic overlap of
either sporadic or familial AAA and autoimmune disorders. The primary function of HAMP is in
iron metabolism, but it also has antimicrobial function in macrophages. Similar to the severe
phenotype seen with mutation in PEPD, mutations in HAMP result in juvenile hereditary
hemochromatosis258, suggesting that any risk alleles for AAA would be due to tissue-specific
alternative splicing or transcription, but not drastically alter normal gene function.
It is also possible that our observed association was spurious, the result of population
stratification or random chance. A recent association study examining SNPs from the
chromosome 19 linkage interval in the Dutch population did find several nominally associated
SNPs but none remained significant for multiple testing259. Interestingly, the SNP showing the
strongest evidence of association resided in CEPBG, which is in agreement with our
observation of association in the region of CEBPG and PEPD.
5.1.3 Sequence Analysis of Candidate Genes
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Both

PEPD

and

CD22,

but

not

CEBPG,

had polymorphic

coding

regions.

Polymorphisms that did not result in amino acid substitution or changes to the 3’ UTR were not
considered further, since their functional effects are hard to predict and therefore, without further
evidence of association, were not considered worth additional follow-up. Although in silico
predictions will not predict all of the effects of sequence changes, we did not consider functional
testing to be warranted unless the specific variants were demonstrated to show further evidence
by association or clustering within familial cases. After investigation for predicted functional
consequences, all of the sequence changes identified in the coding regions or 3’ UTR of CD22
and PEPD appeared to be tolerated. With respect to PEPD, it was not surprising that the
sequence variants had no predicted deleterious effects, given the phenotypes associated with
loss of gene function. Rather, it is more likely that a risk allele would result in increased PEPD
activity or a gain-of-function in vascular tissue. With respect to CD22, although there were no
predicted functional changes, it is of note that for two pairs of SNPs, rs10406069-rs73031792
and rs45453699-40529534, the variant alleles were seen in a similar set of samples suggesting
the presence of two different LD blocks. Furthermore, the rs10406069 A allele and rs45453699
T allele were present in AAA cases only, whereas the other two SNPs were identified in both
control cases. Based upon the small sample size, particularly with only two controls analyzed,
one should not draw conclusions. Given that both of these SNPs are common in the population
(MAF ~ 0.20), however, they would be appropriate for further association testing.
5.2 Identification of Regionally Expressed Candidate Genes
5.2.1 Spatially Expressed Candidate Genes
The results of this study provide evidence of specific gene expression differences
between the descending thoracic and abdominal aorta. Several of these genes are interesting
functional candidates for further study. For example, both TGFBI, which is an extracellular
matrix protein that mediates adhesion of cells to collagen through interaction with integrins, and
AIF1L, which is closely related to the inflammatory signaling molecule AIF1, could plausibly be
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involved in AAA etiology and pathogenesis. Since several of the HOX transcription factors were
identified and since regional expression differences are consistent with previous research, we
chose to focus further study on these genes.
Based on current understanding of collinear expression of HOX genes, the expression
patterns we observed were reasonable. In the thoracic aorta genes from paralogous groups 1-4
exhibited the highest expression, two of which, HOXA2 and HOXA4, had decreasing expression
from the thoracic to abdominal aorta. These genes show similar expression in the developing
lung260,261, so it is possible they may have similar expression patterns in the vasculature. HOXB4
also appeared to show decreasing expression starting at a point in the descending thoracic
aorta, but the regression slope was not significantly different from zero. HOXA3, which has been
observed in the superior regions of the murine aorta209, was not detected in neither microarray
platform, although this may have been due to human and baboon sequence differences.
Expression was not also observed in the human samples, suggesting possible microarray probe
problems for this gene. In the abdominal aorta, genes from the paralogous groups 8-10 showed
increased expression, which is consistent with the maximal expression of Hoxc11 in mouse
femoral arteries 209.
Several of the HOX genes we identified have documented vascular function. HOXA5
and HOXB5, which showed consistent levels of expression across most of the aorta, act to
decrease262 and increase262 endothelial cell migration, respectively. HOXA9, which is expressed
as a novel splice variant in endothelial cells215, has also been implicated in upregulating
angiogenic response217,263.
Discrepancies between microarray platforms in the expressed HOX genes suggest one
study weakness, namely that we may not have detected expression of HOX genes based on
either human-baboon sequence differences or problems with the platform used. There was
significant overlap in HOX genes expressed in human and baboon abdominal aorta using the
Sentrix WG-6, with HOXA4 being a notable exception. This indicates that inter-species
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sequence differences were likely a problem for HOXA4 only. Conversely, HOXC8 and HOXC9
were detected in baboon tissue using the HumanRef8 chip but not in either species using the
Sentrix WG-6, suggesting that there were poorly performing probes on the Sentrix WG-6.
5.2.2 Expression of HOX Genes in AAA and Control Tissue
Examination of data from an expression profiling experiment comparing human AAA and
control tissue demonstrated that ten HOX genes were significantly downregulated in AAA.
There have been several reports of HOX genes being downregulated by inflammatory
conditions. Sarno and colleagues showed decreased expression of several genes from the
HOXA cluster upon treatment with interleukin 1ß (IL1B), an inflammatory cytokine that is
significantly upregulated in AAA tissue264. HOXA9 has also been shown to be responsive to
TNF stimulation in endothelial cells, where it is transiently involved in upregulation of E-selectin
(SELE)214,215. Similar to our analysis, a study comparing gene expression in ulcerative colitis,
another immune-mediated disease, and normal colonic mucosa identified HOXA4 as one of two
significantly downregulated genes in diseased tissue265. Another microarray expression profiling
by Seo, et al. also identified several HOX genes, including HOXA4, HOXA5 and HOXC6, as
being associated with susceptibility to atherosclerosis in the thoracic aorta266. The direction and
magnitude of expression changes were not described, however, making further interpretation
difficult.
The functional roles of HOX genes in the vasculature also make them appealing
candidates for further study. Varying roles in regulation of cell proliferation and differentiation
suggest that the downregulation we have observed might alter cell phenotype in disease. As
different HOX genes act through different mechanisms and with opposing effects, it will be
necessary to assess the complement of HOX gene expression at a vascular site in order to fully
understand their functions. At least two of the genes showing spatial or disease-related
expression, HOXC8 and HOXA9, can negatively-regulate SPP1, which has been previously
implicated in AAA pathogenesis. In light of our findings in the association study, coordinated
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regulation by several HOX genes suggests one possible mechanism for how a gene with
widespread expression could contribute to a localized phenotype. For example, under
conditions predisposing to AAA, the complement of HOX genes in the abdominal aorta could
lead maximal upregulation of a gene such as PEPD.
5.2.3 HOXA4 Expression in the Aorta
Although HOXA4 transcript has been previously described in aortic tissue, no further
studies, including HOXA4 protein analyses or studies on the role of HOXA4 in AAA, have been
published so far. Our western blot data demonstrated protein expression of HOXA4 in aortic
tissue and that it differed significantly between the thoracic and abdominal aorta after correction
for beta-actin expression, confirming in principle that our observations from the baboon aorta
microarray study were not simply the result of false positives. Demonstration of protein
expression is important since overall there is weak correlation between protein and transcript
levels of the different genes in the human genome. Furthermore, the HOX loci contain
numerous non-coding RNA transcripts267 that can either overlap with HOX gene sequences or
potentially post-transcriptionally alter HOX gene levels.
Qualitative analysis of HOXA4 protein by immunohistochemistry showed evidence of
protein expression in all three histological layers with staining observed in the nuclei of several
cell types, including ECs and SMCs. This was also shown by in vitro staining of cultured
vascular ECs and SMCs, which demonstrated perinuclear and nuclear localization of HOXA4
protein. The expression of HOXA4 in both ECs and SMCs is interesting, as Pruett and
colleagues observed that Hoxa3 is expressed in both cell types in the mouse vasculature,
whereas Hoxc11 expression was seen in SMCs only. HOXA9 has also been described in both
endothelium and smooth muscle214,215, indicating that this may be characteristic of the HOXA
cluster. Our immunohistochemistry data were limited by the presence of aggregate-staining that
was deemed to be an artifact, most likely a result of calcifications of the aortic wall. Although this
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artifact did not generally overlap with the specific nuclear staining, it did limit us to qualitative,
rather than quantitative analysis.
Given that SMCs express HOXA4, we were concerned that the expression difference
between thoracic and abdominal aorta might simply be a result of the anatomical differences in
smooth muscle content. Adjustment for smooth muscle actin content demonstrated that this was
not the case, although it is not clear if our observations were a result of a smaller percentage of
cells expressing HOXA4 or lower per-cell levels of HOXA4. Although quantification was not
practical due to nature of staining in some aortas, there was some suggestive evidence of an
increased percentage of nuclei expressing HOXA4 in the thoracic sections of adolescent aortas
relative to their abdominal sections. This is consistent with a previous observation that subsets
of cells express Hoxa3 and Hoxc11 in the mouse vasculature209.
Our western blot data, and to a limited degree our immunohistochemistry data,
demonstrated changes in HOXA4 expression with age. A previous study did show that HOX
gene expression differs between fetal and adult rat vascular smooth muscle cells with Hoxa4
detectable only in the adult cells268. Our data showed higher protein levels by western blot in
aortas from young donors, suggesting that HOXA4 may function in vascular growth during
adolescent development and puberty. Immunohistochemical staining observed primarily in
nuclei of SMCs in the medial layer of aortas from adolescent cases further supports the
hypothesis that HOXA4 has an active role in transcriptional regulation. The age-related
decrease in HOXA4 protein observed by western blot suggests that function of HOXA4 may be
diminished over time, either due to the aging process or the development of atherosclerosis.
This correlates with some evidence of qualitative changes by immunohistochemistry. Although
not quantified due to small sample size, there was a trend towards a decrease in specific
nuclear staining in the tissues from older donors. While the presence of intense cytoplasmic
staining also observed in these tissues could represent a real biological effect, it was deemed

70
more likely a result from substrate interaction with calcium deposits normally present in older
tissues.
As our study did not specifically address HOXA4 function, we can only speculate at this
time as to what its role is in aortic biology and disease. Currently, there have been no
comprehensive chromatin immunoprecipitation (ChIP) analyses identifying HOXA4 target
genes. HOXA4 can bind to its own promoter region269 and there is some evidence for HOXA4
regulating the adjacent HOXA5 gene under certain conditions261,270. An analysis of the tyrosine
hydroxylase promoter identified a putative HOXA4 binding site, but this was not confirmed by
ChIP271. Schmeier, et al.272 implicated HOXA4 in the regulation of microRNA genes during
monocyte differentiation, suggesting a possible mechanism for HOX gene regulation of cell type
specific effects. Similar to several other HOX genes, dysregulation of HOXA4 expression, either
by upregulation or downregulation, occurs in malignancies such as leukemias273-275 and ovarian
carcinoma245 where it may be associated with an altered prognosis.
Similar to other HOX genes, HOXA4 does have known function in embryonic patterning.
Its function in embryogenesis does not, however, appear to be critical, which is not surprising
given that it is one of four paralogs with predicted functional redundancy. Targeted disruption of
Hoxa4 results in a relatively mild phenotype; Hoxa4 knockout mice are viable and exhibit only
some deformations of the cervical spine, including a homeotic transformation of the third
cervical vertebra resulting in the presence of a process similar to that found in the second
vertebra suggesting functional redundancy between HOXA4 and other HOX genes 276,277.
Conversely, transgenic mice overexpressing the Hoxa4 gene develop congenital megacolon
due to abnormalities in the enteric nervous system278.
HOXA4 does not appear to be critical to vascular development, with low to undetectable
expression in developing blood vessels279. Unlike the adjacent HOXA3, which is necessary for
proper formation of the aortic arch, neither HOXA4 nor its three paralogs appear to be important
in vascular patterning212,213. In a study by Kirby and colleagues, no detrimental changes were
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observed in aortic arch formation when all four genes were simultaneously disrupted with
antisense RNA280.
Despite not being critical to vascular patterning, our observations suggest that it
functions in differentiated vascular tissue, especially during times of vessel growth. One
possibility is that similar to other HOX genes, HOXA4 helps to regulate vascular cell proliferation
or differentiation. This is supported by an in vitro comparison of ovarian carcinoma cell lines that
showed that cells exhibiting higher levels of HOXA4 expression have decreased motility by
scratch assay245. Another study by the same group also demonstrated that overexpression of
HOXA4 further decreased cell motility and lead to a corresponding increase in ß1 integrin281.
siRNA knockdown of HOXA4 did not ablate ß1 integrin expression, however, which is consistent
with HOX genes having redundant functions. The role of HOXA4 in mediating cell contacts is
further supported by an increase in basal lamina thickness and collagen in the colonic mucosa
of Hoxa4 transgenic mice278. With respect to AAA, significant downregulation of ß1 integrin has
been observed relative to non-diseased aorta149. It is therefore plausible that loss of HOXA4
function in medial SMCs contributes to adverse phenotypic changes in aneurysms including
disruption of cell-cell interactions.
The regulatory mechanisms of HOXA4 also suggest that HOXA4 may be relevant to
vascular function and disease. HOXA4 regulation is complex, involving several mechanisms,
including chromatin remodeling, non-coding RNA, variable 3’ processing, and potentially
multiple splicing282. It is one of several HOX genes to have a retinoic acid response element
(RARE) in its promoter, which, when activated in coordination with an AP-2 transcription
factor283 or by autoregulation269, can upregulate HOXA4 expression. HOXA4 is also TGF-ß
responsive, with TGF-ß stimulation showing an opposing effect to retinoic acid in developing
lung tissue261. Both of these regulatory mechanisms are relevant to AAA pathogenesis. Recent
evidence has shown anti-inflammatory effects of TGF-ß in a mouse model of AAA284. Retinoic
acid stimulation can decrease SMC proliferation and migration285, as well as increase SMC
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production of inflammatory signaling molecules such as IL1B286, SERPINE1 (PAI-1)287, and
adrenomedullin288, all of which have been implicated in AAA. The effects of neither TGF-ß nor
retinoic acid on HOXA4 expression in adult vascular cell types have been explored, however,
nor is there currently evidence of HOXA4 regulating any of these genes. Furthermore, as noted
above, several HOX genes are downregulated after IL1B stimulation, indicating that further work
is necessary to understand the role of HOXA4 in vascular inflammation.
Finally, one important consideration in trying to understand the role of HOXA4 in the
vasculature is that it should be studied in the context of other HOX genes. Evidence
demonstrates that HOXA4 is involved in multi-HOX gene regulatory networks. For example,
Hoxa4 can regulate retinoic acid induced production of Hoxa5 in mice261,270 but cotransfection
with HOXA1 and HOXA5 decreases activation of the HOXA4 promoter289. Furthermore,
functional redundancy, both for processes regulated, such as angiogenesis, as well as specific
target genes, such as SPP1, makes it necessary to assess the mechanisms of several HOX
genes together. Even in the absence of functional redundancy, multiple HOX genes may still
contribute to a particular phenotype, as suggested by the differences between white adipocytes,
which express HOXA4 and HOXD4 and brown adipocytes, which express HOXC4 and
HOXD4290.
Going forward, extensive work will be necessary to characterize the role of HOXA4 in
the vasculature. The next step will be to establish functional relevance of HOXA4 through either
in vitro analyses, such as characterization of the effects of HOXA4 overexpression or
knockdown, or the use of animal models. As little is known about its transcriptional targets, ChIP
assays to identify target genes of HOXA4 and other HOX genes would be another important
step in understanding HOXA4 function.
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CHAPTER 6 – CONCLUSION

AAA is a multifactorial disease of the aging population with a combination of several
environmental and genetic risk factors. Studies of late-stage AAA tissue have demonstrated that
AAA is an immune-mediated disease involving ECM breakdown, loss of SMCs, and
inflammatory infiltration of the adventitia and outer media. Epidemiological evidence suggests
that factors including genetic differences, age-related changes to the vasculature, tissue
damage from smoking, and hormonal factors may also contribute. Yet the molecular
mechanisms involved in AAA, especially early in the disease, are still not well understood. The
results described here have identified several functional candidates for better understanding the
etiology and pathogenesis of this disease. Specifically, we have identified two functional
candidate genes in the chromosome 19 interval, CD22 and PEPD, that exhibit nominal evidence
of genetic association in a population of Caucasian individuals and have demonstrated that the
observed association likely not due to changes in coding sequence. We have also
demonstrated by microarray expression profiling that there are regional gene expression
differences in the human aorta and have identified the HOX genes as exhibiting spatial and
disease-related changes in expression. Further analyses using western blotting and
immunohistochemical staining of human aortic tissue samples of one of the HOX genes,
HOXA4, confirmed our microarray results and identified age-related changes in gene
expression.
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Appendix A – Tables
Table 1. Familial prevalence of AAA based on patient interviews.
Study
Patients
Patients with
Familial
Surveyed (N)
Positive History (N) Prevalence (%)
Norrgård et al. 1984 291
87
16
18.4
Johansen and Koepsell 1986 292
250
48
19.2
Powell and Greenhalgh 1987 293
56
20
35.7
294
Johnston and Scobie 1988
666
41
6.1
Cole et al. 1989 295
305
34
11.1
Darling et al. 1989 85
542
82
15.1
Majumder et al. 1991 76
91
13
14.3
Verloes et al. 1995 77
313
39
12.5
Lederle et al. 1997 296
985
91
9.2
297
Lawrence et al. 1998
86
19
22.1
Salkowski et al. 1999 298
72
19
26.4
Rossaak et al. 2001 299
248
48
19.4
Totals
3701
470
Combined Prevalence
12.7
300
Modified from Kuivaniemi & Tromp, 2000 with permission from Landes Bioscience.

Table 2. Prevalence of AAA
ultrasonography screening.
Study
301
Bengtsson et al. 1989
302
Collin & Walton 1989
303
Webster et al. 1991
304
Adamson et al. 1992
305
Bengtsson et al. 1992
104
van der Lugt et al. 1992
306
Adams et al. 1993
307
Moher et al. 1994
308
Fitzgerald et al. 1995
309
Larcos et al. 1995
310
Baird et al. 1995
311
Jaakkola et al. 1996
van der Graaf et al. 1998
312

313

Salo et al. 1999
299
Rossaak et al. 2001
314
Frydman et al. 2003
315
Ogata et al. 2005
316
Badger et al. 2007
Total
1

among

Country
Sweden
UK
USA
UK
Sweden
Netherlands
UK
Canada
Ireland
Australia
Canada
Finland
Netherlands
Finland
New Zealand
Australia
Canada
Northern Ireland

first-degree
1

family

members

1

Brothers (%)
10/35 (28.6)
4/16 (25.0)
5/24 (20.8)
5/25 (20.0)

Sisters (%)
3/52 (5.8)
0/15 (0)
2/30 (6.7)
3/28 (10.7)

16/56 (28.6)
4/23 (17.4)
9/48 (18.8)
13/60 (21.7)

3/52 (5.8)
1/28 (3.6)

7/26 (26.9)
4/45 (8,9)
26/210 (12.4)

3/28 10.7)
1/78 (1.3)

based

on

1

Other (%)
7/103 (6.8)
9/62 (14.5)
6/23 (26.1)

2/65 (3.1)
0/52 (0)

11/238 (4.6)
4/49 (8.2)
64/150 (42.7)
11/98 (11.2)
8/136 (5.8)
186/952 (19.5)

20/126 (15.9)
4/147 (2.7)
2/122 (1.6(
44/771 (5.7)

0/31 (0)
0/42 (0)
37/638 (5.7)

Number of individuals identified with AAA/number of individuals examined by ultrasonography.
Other refers to relatives other than sisters and brothers of the AAA-patient, or the categories of
relatives were not specified. Modified from Kuivaniemi & Tromp, 2000300 with permission from
Landes Bioscience.
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Table 3. Power calculations for genetic association studies. Table shows number of
case/control pairs necessary to detect association at 80% power. Numbers were calculated for
multiple odds ratios assuming either dominant, recessive or additive genetic models. All power
calculations were performed using the Genetic Power Calculator223 assuming a D’ of 0.99 and a
prevalence of 2%.
MAF

Dominant Model

Recessive Model

Additive Model

RR: 1.5

RR: 1.8

RR: 2

RR: 1.5

RR: 1.8

RR: 2

RR: 1.5

RR: 1.8

RR: 2

0.10

611

283

201

36,700

14,600

9431

1716

742

507

0.30

516

259

192

1901

793

529

840

388

276

0.40

659

340

257

989

425

283

783

373

269

Abbreviations: MAF, Minor allele frequency; RR, Relative risk
Used with permission from Kuivaniemi, et al., 2008317.
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Table 4. Samples used for sequencing of CEBPG and CD22. Genomic DNA was isolated
from the blood of AAA cases and controls and underwent whole-genome amplification for use in
PCR amplification. Twenty-four samples were selected for each PCR reaction and were chosen
to represent familial and sporadic AAA.
Sample Lab ID1 Pedigree1 Status Origin
Sex CEBPG CD22
1
VD4779 AAA720
Case2
Netherlands
2
SARAH AAA004
Case2
USA
2
3
MS2998 AAA183
Case
Canada
2
4
24381
AAA160
Case
Canada
5
III-5
AAA101
Case2
Canada
2
6
MS4264 AAA223
Case
Belgium
2
7
MS6747 AAA491
Case
Canada
8
MV0110 AAA702
Case2
Netherlands
2
9
23314
AAA048
Case
USA
2
10
B21
AAA008
Case
England
11
GP1023 AAA005
Case2
USA
12
A81
AAA007
Case
England
13
GP4596 AAA104
Case
Canada
14
23342
AAA116
Case
Canada
15
23103
AAA121
Case
Canada
16
23078
AAA118
Case
Canada
17
MS4194 AAA411
Case
Canada
18
MS4968 AAA449
Case
Canada
19
MV0100 AAA701
Case
Netherlands
20
VD4893 AAA739
Case
Netherlands
21
AV063
AAA212
Case
Belgium
22
C7
AAA009
Case
England
23
GP4692 AAA011
Case
USA
24
GP4421 AAA004
Control USA
25
23312
AAA048
Control USA
26
23443
AAA124
Control Canada
27
MS2748 AAA160
Control Canada
28
23295
AAA132
Control Canada
29
23287
AAA132
Control Canada
1
Laboratory specific identification for sample and family
2
Case in chromosome 19 linked family.
3
Sample not used in every sequencing reaction.

M
F
F
M
F
M
M
M
M
M
F
F
F
F
M
M
M
F
M
M
M
F
F
F
F
F
F
M
M

Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

Yes

Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes3
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes3
Yes3
Yes3
Yes3
Yes3
Yes3
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Table 5. Samples used for sequencing of PEPD. RNA was isolated from skin fibroblasts of
AAA cases and controls and reverse transcribed to cDNA for use in PCR amplification.
Sample

Lab ID1

Status
2

Origin

Sex

Template

30
TAGE
Case
Sweden
M
cDNA
31
HS11
Case
USA
M
cDNA
32
GOTOM
cDNA
33
ZIRIC
cDNA
34
WC12
Case
Canada
cDNA
35
WC15
Case
Canada
cDNA
37
WC16
Case
Canada
cDNA
38
WC20
Case
Canada
cDNA
39
WC14
Case
Canada
cDNA
40
WC18
Case
Canada
cDNA
41
WC19
Case
Canada
cDNA
42
WC26
Case
Canada
cDNA
43
DODT
cDNA
3
44
JOHA
Control
cDNA
45
WACAR
cDNA
46
HS02
Case
USA
F
cDNA4
47
HS03
Case
USA
M
cDNA4
48
HS07
Case
USA
M
cDNA4
49
HS09
Case
USA
M
cDNA4
50
BEJO
Case
M
cDNA4
51
HS12
Case
USA
M
cDNA4
52
HS13
Case
USA
M
cDNA4
53
GOHN
Case
USA
M
cDNA4
54
GOSE
Case
USA
M
cDNA4
1
Laboratory specific identifier
2
Diagnosis of AAA and IA.
3
Patient had osteogenesis imperfecta
4
Sample stored as RNA and reverse transcribed to cDNA.
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Table 6. PCR primer pairs for CEPBG, PEPD and CD22.
Reaction

Sequence

CEBPG
Coding

F: CGTGGAAACCATTGATCACCCT
R: AGCCTCCAATGGGTCTTTGAGTC

PEPD
cDNA #1

F: CATGCATTGGCACCCGGAG
R: CTTGCTGATGCCGTCAAAGGAG

PEPD
cDNA #2

57

Cycling Times
(Seconds)
30-30-60

569

54

60-45-60

1.5

F: TCCATTCCAAGGAGCACTTCAAGG
R: AAAGGAGCAGGTGATGTCGG

544

54

60-45-60

1.5

PEPD
cDNA #3

F: TGGAAAGCCTCTTCGAGCACTA
R: GATTAAAGGTGGGAGCCTGCAAA

1022

54

60-45-60

2.0

CD22
Exon 1

F: AACCCATACACGGAAAGGAAGAAC
R: GGCATCCAATAACCTACCCTACTC

472

56

60-45-60

1.5

CD22
Exon 2

F: GCCAGAGAAACGCTTGAGC
R: CAGAGATACACAAAGACAGCAGGA

527

56

60-45-60

1.5

CD22
Exon 3

F: TGGACAACATAGCAAGACC
R: TGGTGAGAAAGAAAGAGGGAAAG

819

58

60-45-60

1.5

CD22
Exon 4

F: GACTGGAGAGAGGTGGAATGAAG
R: TGAATGAATGAGGCACAAGATAATGATG

732

58

60-45-60

1.5

CD22
Exons 5-6

F: AGAAGTAGAGGAAGTGGGAGG
R: CATCTGCCTTCCCCGTTC

915

58

60-45-60

1.5

CD22
Exons 7-8

F: GCACCAAACCACAGCCAG
R: GCACTCTTCCCCTCCATCAC

1086

58

60-45-60

1.5

CD22
Exons 8-9

F: GCTGGGATGAGGGGATGAAG
R: AGGCTGAGGCGAAAGGATTG

1110

58

60-45-60

1.5

CD22
Exons 1011

F: CCGTTGTCACCCTCTTCCTC
R: ATGTTGGCTACGCTGGTCTC

558

58

60-45-60

1.5

CD22
Exon 12

F: GGGAAACAAGGTGAAGGAAGG
R: GAGTGGGAATGAGGCAGAG

372

56

60-45-60

1.5

CD22
Exon 13

F: CATAAGGGGCTGAAGTTGG
R: GAGTTTTGGAGGTTTGGGGTTAC

866

58

60-45-60

1.5

CD22
Exon 14 #1

F: GGGTGGAATGAAGGAGAGAATG
R: CAGGAGGGACACAAGCAG

564

54

60-45-60

1.5

CD22
Exon 14 #2

F: GTTCTCTTCCACTCTCCTTGCTAC
R: CACTGTGACTCCATTTCCTTCC

537

56

60-45-60

1.5

Abbreviations: bp, base pairs

Product Size
(bp)
640

Annealing
Temp (°C)

MgCl (mM)
1.5
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Table 7. Sequencing primers used for CEBPG, PEPD and CD22.
PCR Reaction
CEPBG
Coding

Primer Sequence
F1: CCTGCTCTCATTTCTACCTGTTCT
F2: CAACGCCGAGAGAGGAACAA
R1: AGCCATTGACATGAGTGGTG
R2: GTGTGTCTTGTGCTTTCTGCT

Tm (°C)
56.3
57.4
55.3
55.9

PEPD
cDNA #1

F: GCTGACGCCGCACTTCAC
R: CTGCCGCTGTCCGTGTTG

59.9
59.6

PEPD
cDNA #2

F: TAGATGAGATTGCCAGCGTC
R: CCCATGTCGAACAGGCAC

54.5
56.4

PEPD
cDNA #3

F1: ATGCGCCACAGCTCCTAC
F2: TGGGTGCCATGAAGCCAG
R1: GCCGTCTCTCGCTACTGG
R2: TCCACGCCCTCTGGGTAG

57.9
58.3
57.8
59.1

CD22
Exon 1

F: TCAGAGCCATAGAGAAGCAGG
R: GGTAAGAGAGACCAGGGAG

56.1
56.4

CD22
Exon 2

F: CATCCCAAATGCCACATCC
R: CTGGGTCTTTCCTCCTCCTC

54.2
56.3

CD22
Exon 3

F: TGGACAACATAGCAAGACC
R: GCCATCGTCATCCGCTG

52.2
56.6

CD22
Exon 4

F: GGTGATTTGGGACAGGACA
R: GAAACACCAGGGCTGACAAG

54.7
56

CD22
Exons 5-6

F: GCACTTTCCACACCCTCC
R: CATCTGCCTTCCCCGTTC

56.2
56

CD22
Exons 7-8

F: ACAGGTAGCGGGAGAAGAG
R: CACTGGTCCCTTCTCTGCTC

56
57.4

CD22
Exons 8-9

F: GGACAGCAAAAGGGACAGG
R: CAGTGAGGTGTCATTATGCGAC

56.1
55.8

CD22
Exons 10-11

F: AGAAGGACGAGTCTGGCTG
R: ATGTTGGCTACGCTGGTCTC

56.5
57.3

CD22
Exon 12

F: GGTGAAGGAAGGGGATAAAATGTC
R: TGGCACAAAGAGGGCAGG

55.6
58.2

CD22
Exon 13

F: TGTTGAGAGGGAGGAGAGTTC
R: TCATAGTCGCCCTGAGAAAACC

55.7
56.7

CD22
Exon 14 #1

F: GGGTGGAATGAAGGAGAGAATG
R: CAGGAGGGACACAAGCAG

55.3
55.6

CD22
Exon 14 #2

F: CCATCTAAATACCTGCCCTGAC
R: AGACTTTCCCCTCTCCTCATC

55.1
55.6

Abbreviations: Tm, Predicted melting point
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Table 8. Tissue samples of baboon aorta used for microarray analysis. Samples were
obtained at necropsy and shipped to Wayne State in RNALater solution. Segment number
refers to approximate anatomic location as described in Figure 4. Quality control measures were
performed on isolated RNA using a Nanodrop spectrophotometer and Agilent Bioanalyzer.
Nanodrop
Conc
(ng/µl)

Bioanalyzer

Aorta

Age

Sex

Segment

RNA ID

1

25

F

2
3
4
5
6
7
8
9
10
12

MS8951
MS8952
MS8953
MS8954
MS8955
MS8956
MS8957
MS8958
MS8959
MS8961

4402
4570

1.97
1.93

3910
4850
5468

1.85
1.85
1.88

3610

1.78

4562

1.82

260/280

Conc
(ng/µl)

28s/18s

RIN

2

7

F

4
5
6
7
8
9
10
11
12

KP031
KP032
KP033
KP034
KP035
KP036
KP037
KP038
KP039

4838
4075
2345
2520
1454
3494
4754
2635
402

1.46
1.96
2.08
2.08
2.08
2.04
1.62
2.07
2.06

977
779
536
667
682
641
670
632
678

1.8
2.2
2.6
2.4
2.3
2.6
1.7
2.7
1
0

6.4
6.7
6.9
6.8
6.8
7.2
6.5
7
6.7

3

22

M

1
2
3
4
5
6
7
8
9
10
11
12

KP053
KP056
KP057
KP058
KP059
KP060
KP061
KP062
KP063
KP064
KP065
KP066

115
4158
3104
3133
2175
2079
1309
3120
1645
1164
2061
3750

1.92
1.94
2.06
2.06
2.07
2.08
2.08
2.06
2.08
2.08
2.07
2.02

40
641
725
730
723
494
1016
587
944
583
1132
567

1.8
1.8
1.9
1.8
2.5
2.7
2.4
2.3
2.3
2.4
2.4
2.0

N/A
6.3
6.4
2
N/A
6.5
6.6
7.8
6.4
7.8
7.8
7.4
6.4

1

2

Electrophoretic trace did not align with control sample.
Electrophoresis trace was examined manually and was included; Sample did not differ in
microarray QC.
Abbreviations: Conc., concentration; RIN, RNA integrity number
2
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Table 9. Human tissue samples from non-aneurysmal aortas used in assessing protein
expression of HOXA4. Samples were obtained at autopsy and either flash frozen for
preparation of protein homogenates, embedded in OCT media, or fixed in formalin.
Case
ID

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
1

Sample ID
Western Blotting
Thor

Abd

1096
1159
1205
8001
8013
8025
8076
8056
8086
8099
8105
8118
1016
1048
1032
1124
8005
8034
8132
8139
8147
8163
8174
8181
N.A.

1104
1194
1240
8006
8021
8031
8084
8062
8094
8101
8110
8127
1028
1064
1044
1140
8010
8044
8137
8143
8151
8169
8182
8188
N.A.

1

IHC (Frozen/FFPE)
Thor

Race

Sex

Cause of
Death

21
50
78
4
41
28
54
69
52
59
54
39
53
14
53
20
10
48
20
23
49
49
53
44
88

W
B
W
B
B
B
W
W
W
W
B
W
W
B
W
B
B
B
B
B
B
B
B
W
W

M
M
M
M
M
M
M
F
F
F
M
F
M
F
M
M
M
F
M
M
M
F
M
M
F

Overdose
Overdose
CA
Unknown
Heart Failure
CA
CA
Trauma
CA
CA
GSW
Unknown
GSW
Suicide
Overdose
GSW
GSW
Trauma
Trauma
GSW
CA
Overdose
CA
Overdose
Trauma

Abd

1206/1199
9000/6000

1237/1242
9003/6007

9023/N.A.

9031/N.A.
N.A./6094
9058/6074

9052/6065

Age
(years)

N.A./6115

1049/N.A.

1065/N.A.
N.A./1038

9005/N.A.

9010/N.A.
N.A./6051

N.A./6204
N.A./6183

Sample ID is JL number (ie. 1096 is JL1096).
Abbreviations: GSW, gunshot wound; CA, cardiac arrest; N.A., not available; W, white; B, black;
Thor, Thoracic; Abd, Abdominal; FFPE, formalin-fixed, paraffin-embedded.
Table 10. Human AAA samples used in immunohistochemistry of CD22 and PEPD.
Samples were obtained as part of elective repair operations and would have been otherwise
discarded. All patients were Caucasians.
ID
Age (years)
Sex
AAA1
AAA2
AAA3
AAA4
AAA5

72
67
87
67
64

M
M
F
M
M
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Table 11. Primary antibodies used in western blots and immunohistochemical staining.
Antibodies were selected on criteria of literature evidence when possible, predicted epitope
specificity, and manufacturer recommended applications.
Target

Antibody

Manufacturer

Species

WB
Dilution

WB Load
(µg protein)

IHC Dilution

HOXA4
ACTB
ACTA2
PEPD

ab26097
A1978
ab5694
12218-1-AP

Rabbit polyclonal
Mouse monoclonal
Rabbit polyclonal
Rabbit polyclonal

1:2000
1:10,000
1:5000
N.A.

20
20
0.5
N.A.

1:100-1:131
N/A
N/A
1:75

CD22

ab953

Abcam
Sigma
Abcam
Proteintech
Group, Inc.
Abcam

Mouse monoclonal

N.A.

N.A.

1:100

Abbreviations: WB, western blot; IHC, immunohistochemical staining
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Table 12. Functional positional candidate genes studied by genetic association. Ten
genes were identified within the AAA linkage intervals on chromosomes 4 and 19 with
annotated GO or KEGG functions relevant to AAA. mRNA expression levels for each gene in
both AAA and control abdominal aortic tissue, as well as a score indicating the differences in
expression levels (Diff score), were obtained from previous work by the laboratory48.
Gene

Symbol

Chr

GO Category

KEGG Pathway

# of
SNPs

AAA
Exp

Cont
Exp

Diff
1
Score

Peptidase D

PEPD

19

N.A.

N.A.

25

1299.7

956.6

10.52

CCAAT-enhancer
binding protein G

CEBPG

19

immune
response;
others

N.A.

2

222.0

251.5

-3.27

CCAAT-enhancer
binding protein A

CEBPA

19

myeloid cell
differentiation

N.A.

16

630.2

118.0

31.32*

Glucose phosphate
isomerase

GPI

19

humoral
immune
response

N.A.

5

1135.9

758.5

11.57

Hepcidin
antimicrobial
peptide

HAMP

19

immune
response;
others

N.A.

1

135.7

N.D.

13.57

CD22 molecule

CD22

19

immune
response;
others

B cell receptor
signaling pathway

4

578.1

N.D.

16.17

Nuclear factor of
kappa light
polypeptide gene
enhancer in B-cells
inhibitor, delta

NFKBID

19

inflammatory
response

N.A.

1

2

22.4

N.D.

23.80*

TYRO protein
tyrosine kinase
binding protein

TYROBP

19

cellular
defense
response

natural killer cell
mediated
cytotoxicity

1

2

4973.0

801.2

41.15*

Hematopoietic cell
signal transducer

HCST

19

N.A.

natural killer cell
mediated
cytotoxicity

0

2

736.4

147.7

33.44*

Interleukin 15

IL15

4

immune
response;
others

cytokine-cytokine
receptor
interaction

11

141.1

136.7

0.62

1

The Diff Score is generated using a custom algorithm from Illumina. A Diff Score of 13
corresponds to an approximate p value of 0.05. Genes marked with an asterix (*) were
significantly different between AAA and control tissues after correction for multiple testing (FDR
< 0.05).
2
HCST, TYROBP, and NFKBID are adjacent in the genome. Although no SNPs were
genotyped in HCST, the two SNPs selected were chosen to represent the major haplotype
blocks in that genomic region. Similarly, CEPBG and PEPD are adjacent in the genome.
Abbreviations: Chr, chromosome; N.A., not applicable; N.D., not detected; Exp, Expression;
Cont, Control
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Table 13. Results of candidate gene association for SNPs in or around candidate genes
with nominal p < 0.05. Tests for allelic and genotypic association were carried out by a χ2 test
and logistic regression, respectively for each SNP. P-values < 0.05 are shown in bold. For
logistic regression, SNPs with LRT and Wald test p-values < 0.05 were considered nominally
associated.
SNP

χ 2 p-value

Gene
Combined

Canadian

Belgian

LRT

Wald

p-value

p-value

rs756796

CD22

0.020

0.1179

0.0680

0.017

0.016

rs2267574

CD22

0.011

0.0047

0.4185

0.019

0.016

rs889140*

PEPD

0.0043

0.0248

0.0513

0.0025

0.002

rs7248389*

PEPD

0.0009

0.0220

0.0084

0.001

0.0008

rs7250833

PEPD

0.032

0.1582

0.0987

0.043

0.042

rs2241380

PEPD

0.018

0.0831

0.1536

0.035

0.034

rs11880064

PEPD

0.037

0.1045

0.2124

0.059

0.058

rs580391

GPI

0.052

0.1143

0.4012

0.040

0.038

rs7251432
HAMP
0.036
0.0296
0.5193
*SNP was out of Hardy-Weinberg equilibrium in Belgian controls
Abbreviations: LRT, likelihood ratio test

0.051

0.050
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Table 14. Sequence changes detected by cDNA sequencing of PEPD.

1
2
3
4
5
6
7
1

Chr. Pos.
1
(Build 37)

Gene
Feature

Allele
Change

rs/hCV
Number

MAF
1
(Caucasian)

mRNA
Pos

AA

Residue
1
Change

33,953,912
33,902,652
33,882,255
33,882,222
33,878,845
33,878,837
33,878,340

Exon 9
Exon 11
Exon 13
Exon 13
Exon 14
Exon 14
Exon 15

T->C
T->C
C->T
C->T
G->A
C->T
G->T

rs3745969
rs74988985

0.063 (N.D.)
0.021 (N.D.)
0.021
0.104 (0.155)
0.021
0.229 (0.246)
0.021

793
877
1231
1264
1427
1436
1525

220
248
366
377
432
435
464

Y->Y
G->G
H->H
H->H
A->T
L->F
L->L

rs17569
rs17570

Chromosomal position and minor allele frequency obtained from the National Center for
Biotechnology Information (NCBI). Caucasian refers to MAF in the HapMap CEU or other
Caucasian population available at the NCBI website. Single letter amino acids codes are used
in Residue Change column.
Abbreviations: Chr. Pos., Chromosomal position; rs/hCV, RefSeq, human Craig Venter; MAF,
minor allele frequency; AA, amino acid.
Table 15. PEPD sequence changes by sample number.
Sample
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
1

1

1
T/T
T/T
T/T
T/T
T/T
T/C
T/T
T/C
T/T
T/T
T/T
T/T
T/T
T/T
T/T
T/T
T/T
T/T
T/T
T/C
T/T
T/T
T/T
T/T

2
T/T
T/T
T/T
T/T
T/T
T/T
T/T
T/T
T/T
T/T
T/T
T/T
T/T
T/T
T/T
T/T
T/T
T/T
T/T
T/C
T/T
T/T
T/T
T/T

3
C/T
C/C
C/C
C/C
C/C
C/C
C/C
C/C
C/C
C/C
C/C
C/C
C/C
C/C
C/C
C/C
C/C
C/C
C/C
C/C
C/C
C/C
C/C
C/C

Sequence Change
4
C/C
C/C
C/C
C/C
C/T
C/C
C/C
C/C
C/C
C/C
C/C
C/T
C/T
C/T
C/C
C/C
C/C
C/C
C/C
C/C
C/C
C/T
C/C
C/C

1

5
G/G
G/G
G/G
G/G
G/G
G/G
G/G
G/G
G/G
G/G
G/G
G/G
G/G
G/G
G/G
G/G
G/G
G/G
G/G
G/G
G/G
G/A
G/G
G/G

6
C/T
C/C
C/T
C/C
C/C
C/C
T/T
C/C
C/T
C/C
T/T
C/C
C/C
C/T
C/C
C/T
C/C
C/C
C/T
C/C
C/T
C/C
C/C
C/C

7
G/G
G/G
G/G
G/G
G/G
G/G
G/G
G/G
G/G
G/G
G/G
G/G
G/G
G/G
G/G
G/G
G/T
G/G
G/G
G/G
G/G
G/G
G/G
G/G

Sequence Change indicates the genotype at the corresponding position from table 14 for each
individual whose DNA was sequenced. Sample number refers to samples described in Table 5
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Table 16. Sequence changes identified by CD22 exon sequencing.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
1

Chr. Pos.
(Build 37)

Gene
Feature

Allele
Change

rs/hCV Number

MAF
(Caucasian)

35,823,999
35,824,019
35,829,381
35,831,986
35,832,381
35,832,886
35,835,940
35,836,512
35,836,530
35,836,600
35,837,148
35,837,150
35,837,327
35,837,428
35,837,694
35,837,705
35,837,724-5
35,837,813
35,837,846
35,838,076

Intron 3
Intron 3
Intron 6
Exon 7
Exon 8
Intron 9
Intron 10
Exon 12
Exon 12
Exon 12
Intron 13
Intron 13
Intron 13
Intron 13
3’ UTR
3’ UTR
3’ UTR
3’ UTR
3’ UTR
3’ UTR

C->T
C->G
A->G*
C->T
G->A
T->A
C->T
A->G
G->A
C->A
G->A
C->T
C->T
G->A
C->T
A->G
1
GC I/D
C->T
C->T
C->T

rs881456
rs10419538
rs7248108
rs25677

0.021 (0.000)
0.104 (0.181)
0.042 (0.042)
0.042 (0.000)
0.021
0.021
0.313 (N.D.)
0.021
0.104 (0.292)
0.042 (N.D.)
0.021 (0.05)
0.021
0.063 (N.D.)
0.208 (0.383)
0.250 (N.D.)
0.167 (N.D.)
0.042 (N.D.)
0.042
0.042 (0.000)
0.042 (0.055)

rs45453699
rs10406069
rs34826052
hCV25603572
rs58156121
rs12985354
rs73031792
rs35529786
rs34472317
rs16970255
rs3088063

mRNA
Pos

AA

Residue
Change

1529
1721

484
548

C->C
R->K

2293
2311
2381

739
745
768

R->G
G->D
P->P

2715
2726
2745-6
2834
2867
3097

Variant allele is GC insertion
For definitions, see footnote to Table 14.
Table 17. CD22 sequence changes by sample number.
Sequence Change
Sample

2

2

1

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

1

C/C

C/C

A/G

C/C

G/G

T/T

C/T

A/A

G/G

C/A

G/G

C/C

C/T

G/G

C/T

A/A

-/-

C/T

C/C

C/C

2

C/C

C/C

A/A

C/C

G/A

T/T

C/T

A/A

G/G

C/C

G/G

C/C

C/C

G/G

C/C

A/A

-/-

C/C

C/C

C/T

3

C/C

C/G

A/A

C/C

G/G

T/T

C/C

A/A

G/A

C/C

G/A

C/C

C/C

G/A

C/C

A/G

-/+

C/C

C/T

C/C

4

C/C

C/C

A/A

C/C

G/G

T/T

C/T

A/G

G/G

C/C

G/G

C/C

C/C

G/G

C/T

A/A

-/-

C/C

C/C

C/C

6

C/C

C/C

A/A

C/C

G/G

T/T

C/T

A/A

G/G

C/C

G/G

C/C

C/C

G/A

C/T

A/A

-/-

C/C

C/C

C/C

7

C/C

C/C

A/A

C/C

G/G

T/T

C/T

A/A

G/G

C/C

G/G

C/C

C/C

G/G

C/C

A/A

-/-

C/C

C/C

C/C

8

C/C

C/G

A/A

C/C

G/G

T/T

T/T

A/A

G/G

C/C

G/G

C/C

C/C

G/G

C/C

A/A

-/-

C/C

C/C

C/C

9

C/C

C/C

A/A

C/C

G/G

T/T

C/C

A/A

G/A

C/C

G/G

C/C

C/C

G/A

C/C

A/G

-/-

C/C

C/C

C/C

10

C/C

C/C

A/A

C/C

G/G

T/T

C/T

A/A

G/G

C/C

G/G

C/C

C/C

G/G

C/T

A/A

-/-

C/C

C/C

C/C

11

C/C

C/G

A/A

C/C

G/G

T/T

C/C

A/A

G/A

C/C

G/G

C/C

C/C

G/A

C/C

A/G

-/-

C/C

C/C

C/C

12

C/C

C/C

A/A

G/G

T/A

C/C

A/A

G/A

C/C

G/G

C/C

C/C

G/A

C/C

A/G

-/-

C/C

C/C

C/C

13

C/C

C/C

A/A

C/C

G/G

T/T

C/T

A/A

G/G

C/C

G/G

C/C

C/C

G/G

C/T

A/A

-/-

C/C

C/C

C/C

14

C/T

C/C

A/A

C/C

G/G

T/T

C/C

A/A

G/G

C/C

G/G

C/C

C/C

G/G

C/C

A/G

-/-

C/C

C/C

C/C

17

C/C

C/C

A/A

C/C

G/G

T/T

C/T

A/A

G/G

C/C

G/G

C/C

C/C

G/G

C/T

A/A

-/-

C/C

C/C

C/C

18

C/C

C/C

A/A

C/C

G/G

T/T

C/T

A/A

G/G

C/C

G/G

C/T

C/T

G/A

C/C

A/G

-/-

C/C

C/C

C/C

19

C/C

C/C

A/A

C/C

G/G

T/T

C/T

A/A

G/G

C/C

G/G

C/C

C/C

G/A

T/T

A/A

-/-

C/C

C/C

C/C

20

C/C

C/C

A/A

C/C

G/G

T/T

C/C

A/A

G/G

C/C

G/G

C/C

C/C

G/G

C/C

A/A

-/-

C/C

C/C

C/C

21

C/C

C/C

A/A

C/T

G/G

T/T

C/C

A/A

G/G

C/C

G/G

C/C

C/C

G/G

C/C

A/A

-/-

C/C

C/C

C/C

22

C/C

G/G

A/A

C/C

G/G

T/T

C/T

A/A

G/A

C/C

G/G

C/C

C/C

G/A

C/T

A/G

-/-

C/C

C/C

C/C

23

C/C

C/C

A/A

C/C

G/G

T/T

C/C

A/A

G/G

C/C

G/G

C/C

C/C

G/G

C/C

A/A

-/-

C/C

C/C

C/T

24

C/C

C/C

A/G

C/T

G/G

T/T

C/C

A/A

G/G

C/A

G/G

C/C

C/T

G/G

C/C

A/A

-/+

C/T

C/T

C/C

25

C/C

C/C

A/A

C/C

G/G

T/T

T/T

A/A

G/G

C/C

G/G

C/C

C/C

G/G

C/T

A/A

-/-

C/C

C/C

C/C

A/A

G/G

C/C

A/A

G/G

C/C

G/G

C/C

C/C

G/A

C/T

A/A

-/-

C/C

C/C

C/C

G/G

C/C

C/C

G/A

C/T

A/G

-/-

C/C

C/C

C/C

26
27

C/C

C/C

A/A

C/C

G/G

T/T

C/C

28

C/C

C/C

A/A

C/C

G/G

T/T

C/C

29

1

C/C

-/+ = deletion/GC insertion
Genotypes at the corresponding position from table 16 for each individual whose DNA was
sequenced as described in Table 4.
2
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Table 18. Genes identified by linear regression analysis of baboon microarray data.
Linear regression analysis was conducted for segment number versus expression on each gene
probed by the Sentrix WG-6 and HumanRef-8 microarray platforms. Regression line slopes and
99% CIs are shown for each gene with a slope different from zero in both platforms.
Gene ID Gene
Sentrix WG-6
HumanRef-8
Symbol
Slope
99% C.I
Slope
99% C.I
Lower
Upper
Lower
Upper
133
ADM
10.1
3.6
16.6
6.0
1.2
10.8
419
ART3
26.9
4.5
49.3
199.3
18.4
380.1
1031
CDKN2C
-14.5
-26.3
-2.7
-28.1
-53.8
-2.3
1687
DFNA5
-36.5
-48.0
-25.0
-264.7
-513.1
-16.3
3199
HOXA2
-15.8
-21.1
-10.6
-69.7
-118.0
-21.3
3205
HOXA9
22.7
7.8
37.6
212.8
70.1
355.5
3223
HOXC6
70.5
33.2
107.9
418.3
30.9
805.8
6647
SOD1
-34.5
-59.0
-10.1
-263.9
-524.6
-3.1
7025
NR2F1
24.5
8.2
40.8
82.3
9.0
155.7
7035
TFPI
6.9
1.7
12.1
41.3
5.3
77.2
7045
TGFBI
68.2
34.7
101.8
364.7
61.0
668.4
8428
STK24
40.2
3.2
77.1
216.1
30.2
401.9
10397
NDRG1
72.8
4.8
140.8
266.1
66.0
466.3
10409
BASP1
74.3
5.6
143.1
281.4
60.7
502.2
25807
RHBDD3
-14.1
-22.2
-6.0
-56.3
-94.5
-18.0
56994
CHPT1
-21.2
-34.4
-8.0
-97.0
-166.76
-27.23
83543
AIF1L
180.1
33.5
326.8
1050.8
177.4
1924.2
83716
CRISPLD2
30.6
14.7
46.6
148.2
0.2
296.2
84518
CNFN
-25.1
-49.3
-0.8
-86.1
-158.8
-13.3
93664
CADPS2
-5.6
-11.0
-0.3
-82.3
-147.4
-17.1
126823
KLHDC9
-8.4
-14.1
-2.8
-17.3
-33.2
-1.5
138046
RALYL
9.1
0.3
17.9
66.4
13.1
119.6
154791
C7orf55
-37.2
-55.5
-18.9
-46.5
-92.7
-0.3
Abbreviations: 99% CI, 99 percent confidence interval.
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Appendix B – Figures
Figure 1. Sites of aneurysmal disease in the aorta. Several regions of the aorta are prone to
aneurysm formation, including the ascending aorta, proximal descending aorta and infrarenal
abdominal aorta. The abdominal aorta is the most common site, with a prevalence of
aneurysmal disease six times greater than the thoracic aorta. Image courtesy of Marc Nischan
and reproduced with permission from Nischan, et al., 2010318.

89
Figure 2. Gross appearance of an AAA. Image of an 5.5 cm unruptured AAA in a 74-year-old
Japanese male obtained during elective open surgical repair. Image courtesy of Yoshiki Kyo,
M.D. from the Department of Cardiovascular Surgery, Higashihirosima Medical Center,
Hiroshima, Japan. Reproduced with permission from Nischan, et al., 2010318.

90
Figure 3. Images of PCR product bands used in candidate gene sequencing. PCR
products for CEPBG (A), PEPD (B) and CD22 (C) (see Table 5 for primer information) were
electrophoresed in agarose gels (variable concentration) and stained with ethidium bromide.
100 bp ladder marker (D) or Lambda DNA-BstE II Digest (E) from New England Biolabs
(Ipswich, MA) were used to assess product molecular weight depending upon predicted product
size.
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Figure 4. Diagram of section numbering used for baboon aortas. Anatomical landmarks,
including the aortic arch (section 1), renal arteries (section 8) and iliac bifurcation (section 12),
were used for segment numbering to allow for cross-comparison of baboon aortas during
microarray analysis.

92
Figure 5. Dissection of baboon aortic tissue. Images showing RNALater-treated aortic
sample (A). Samples were stripped of the gross adventitial fibrous tissue, minced, with a scalpel
(B) and used for RNA isolation.
A

B

93
Figure 6. Principle components analysis (PCA) of microarray signal data. PCA was
performed on normalized signal from the Sentrix WG6 (A) and HumanRef8 data (B) in order to
determine the presence of any outlier samples. No samples were considered significant outliers
or excluded by PCA. In the HumanRef8 arrays, samples tended to group by animal of origin. (B
= baboon; S = Segment; i.e. B1.S1 – Baboon1.Segment 1)
A

94
Figure 6 Cont.
B

95
Figure 7. Representative SDS-PAGE gel of protein homogenates used in western
blotting. 7.5 µg of protein was loaded on gels, electrophoresed, and stained using a Rapid
Coomassie protocol. No evidence of significant protein degradation was observed in any of the
48 samples used in western blotting. Samples used in western blotting are labeled at top. Other
lanes are aortic tissue not analyzed by western blot. Protein marker (Novex Sharp Prestained
Protein Standard, Invitrogen Corporation, Carlsbad, CA) is on shown on the right with band
sizes indicated in kDa.
®

96
Figure 8. Linkage disequilibrium (LD) plot of genotyped SNPs in CEBPG and PEPD.
Genotype frequency data for each SNP genotyped in the region of CEBPG and PEPD were
downloaded from the HapMap project and input into Haploview software. The LD plot was
constructed using r2 as the LD statistic, with black indicating 100% LD and white indicating no
LD. SNPs marked with an asterix (*) were nominally associated with AAA.
A

97
Figure 9. LD plot of validated SNPs from the HapMap project in the region of CD22. LD
plot was constructed in a manner similar to that described for Figure 8. SNPs indicated in red
were genotyped and SNPs indicated in blue are appropriate for further study based on the
criterion of a MAF of > 0.05.
B

98
Figure 10. Immunohistochemistry of CD22 and PEPD demonstrates expression in aortic
tissue. Immunohistochemical staining using antibodies against CD22 (A) or PEPD (B) was
performed on formalin-fixed paraffin embedded tissue sections of abdominal aorta and AAA and
either tonsil or kidney as positive controls. Negative control staining with non-immune serum
showed no cross-reactivity of the primary antibodies (data not shown). Regions of positive
staining appear reddish-brown (indicated by black arrows) with hematoxylin counterstaining in
blue.

99
Figure 10 cont.

100
Figure 11. Sequence variants identified by candidate gene sequencing. Variants in PEPD
(A) and CD22 (B) plotted to show their relative chromosomal positions and positions relative to
gene features.

101
Figure 12: Predicted effects of A432T and L435F amino acid substitutions on the
structure of PEPD. Model structures were generated using Swiss-Model Software (Template
2iw2A.pdb). Superimposed structural differences of wild-type (colored) and mutant (white)
amino acids are shown in full protein (A) and detailed (B) views.
A

B

102
Figure 13. Predicted miRNA binding sites in the 3’ UTR of CD22 that overlap sequence
variants identified by DNA sequencing. Predicted miRNA binding sites were identified using
the MirBase Targets database234,235. The sequence variants rs73031792 (A) and rs16970255
(B), indicated in black, were located in the predicted binding sites of miRNAs shown.
A
hsa-miR-933
CUCCAGAGGGACGCGUGU
|: || :|||||||:||
GGCTTCCTCCTGCGCGCA
hsa-miR-560
CCGCCGGCCGGC-CGCGUGCG
||| || |:| |||||:|:
GGCTTCCTCCTGCGCGCATGT
B
hsa-miR-490-5p
GGUGGACCUCUAGGUA
|:||| || ||||||
CTACCCAGAAATCCAT
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Figure 14. Spatial expression changes in HOX genes in baboon aortic tissue. Log2
transformed expression data HOX genes detected in baboon aortas using both microarray
platforms (A), HumanRef8 only (B) or Sentrix WG6 only (C). Expression is plotted against aortic
segment (as described in Figure 4). Sentrix WG6 (Red) and HumanRef8 (Blue) data are plotted
on different Y-axis scales to allow for comparison of expression pattern. Genes in bold had
statistically significant expression patterns by linear regression.

104
Figure 14 cont.

105
Figure 15. HOX gene transcripts are significantly decreased in AAA tissue compared with
controls. Box-and-whiskers plot of gene expression data of HOX genes with significantly
different expression between AAA (n = 7) and abdominal aortic control (n = 7) tissue. HOXA4
(second from left) was the most significantly differentially expressed HOX gene.
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Figure 16. Immunohistochemical staining shows HOXA4 protein in aortic tissue. A:
Immunohistochemical staining (reddish-brown) of both frozen and FFPE thoracic aortic sections
showing evidence of HOXA4 in all three histological layers. B: High-power objective (40X)
images showing staining were primarily present in the nuclei of ECs and SMCs (Black arrows).
C: Thoracic aorta of a 78 y.o. (40X) showing aggregate-like staining artifact present in several
sections. D-E: Tissue localization of staining did not appear to differ between thoracic and
abdominal aorta. Although there was a visible trend towards increased thoracic staining,
quantification was not performed due to the aggregate-like staining.

107
Figure 16 cont.

108
Figure 16 cont.

109
Figure 17. Aortic tissue sections from adolescent and adult donors exhibit different
staining patterns. Immunohistochemical staining of both frozen (A) and FFPE (B) tissue
sections exhibited primarily nuclear and perinuclear staining in sections from adolescent donors
(black arrows). Nuclear staining was observed in tissue from adult donors but most staining was
the intense aggregate-like staining deemed to likely be nonspecific (white arrows).

110
Figure 17, cont.

111
Figure 18. Protein bands observed by western blot analysis. Representative western blots
lanes using antibodies directed against HOXA4 (A, B), ACTA2 (C), and ACTB (D).
Chemiluminescence and epi-luminescent exposures of the blots were obtained sequentially and
overlaid to visualize bands and molecular weight markers, respectively. Relevant marker band
sizes are labeled to the left of images. Protein bands were observed at the expected molecular
weights of ~33 kDa (A), ~42 kDa (C), and ~42 kDa (D). Reactivity against the immunizing
peptide (ab32311, Abcam Inc., Cambridge, MA) was assessed with the HOXA4 antibody (B).

112
Figure 19. Western blots of HOXA4, ACTA2, and ACTB on paired thoracic and abdominal
aortic tissue samples. Bands for each protein from all 48 samples used for quantification of
HOXA4 are shown. Sample refers to sample number described in table 9. Note: HOXA4 bands
for sample five and ACTA2 bands for samples 1-4 and 5-8 were loaded out of order and have
been rearranged for this figure. T = Thoracic, A = Abdominal.

113
Figure 20. HOXA4 protein levels are significantly in decreased in abdominal aorta
compared to thoracic aorta. HOXA4 band intensity was quantified using BioRad Quantity One
Software and adjusted for band beta-actin (A) and smooth muscle alpha actin expression (B).
Boxes represent 25-75 percentiles and whiskers represent 1.5 times the interquartile range.
Expression between thoracic and abdominal tissues was compared using a Wilcoxon signed
rank test as the test statistic. * = p < 0.0001, ** = p < 0.001.

114
Figure 21. HOXA4 shows decreasing expression with age. Regression lines were calculated
using beta-actin adjusted HOXA4 protein levels for age versus either thoracic or abdominal
protein expression. Slopes were significantly different from zero for both aortic locations
(Thoracic: slope = -0.95 (99% C.I. -1.66, -0.24); R2 = 0.43; F-statistic p =. 0.0005. Abdominal:
slope = -0.58 (99% C.I. -1.02, -0.13); R2 = 0.41; F-statistic p = 0.00075).

115
Figure 22. HOXA4 localizes to the perinuclear region in vascular cells. Cultured primary
HAECs (A,B), (PromoCell, ScienCell Research Laboratories) and HASMCs (C,D) (ScienCell,
ATCC) were used for immunofluorescent staining. Staining with anti-HOXA4 antibody and a
fluorescein conjugated secondary revealed HOXA4 is shown in green. Cell structure was
visualized in red using rhodamine-phalloidin to stain filamentous actin. Nuclei were visualized in
blue using DAPI.
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Abstract
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by
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Degree: Doctor of Philosophy
Abdominal aortic aneurysm (AAA) is a common disease for which mechanisms of
formation are still not well understood. Despite a strong genetic component to AAA risk, specific
risk alleles are still largely unidentified. AAA is also a localized disease with a majority occurring
in the infrarenal abdominal aorta and is six times more common than aneurysms of the thoracic
aorta. To determine whether risk alleles are present in functional positional candidate genes.
we: 1. performed a genetic association study using DNA from AAA cases and controls in ten
candidate genes and 2. performed exon sequencing on three genes with evidence of nominal
association. To identify genes with regional expression in the aorta of potential relevance to
AAA: 1. Illumina microarrays were used to perform a gene expression profiling of entire baboon
aortas and 2. protein expression of one candidate gene, HOXA4, was examined in further detail.
Single nucleotide polymorphisms in three positional candidate genes, CEBPG, PEPD
and CD22, that had both functions relevant to AAA and expression in AAA tissue exhibited
nominal association and further studied by DNA sequencing of exons. Sequence variants were
identified in PEPD and CD22, but not CEPBG, but no sequence variants had predicted
functional changes. Analysis of the gene expression profiles from whole length baboon aortas
identified 26 genes that exhibited lengthwise expression changes along aorta, including three
genes from the homeobox (HOX) family of transcription factors. Comparison of HOX gene
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transcripts between AAA and control abdominal aortic tissue identified ten HOX genes that were
significantly downregulated in AAA tissue. The most significantly downregulated HOX gene,
HOXA4, also exhibited spatial expression changes and was studied in human aortic tissue.
Immunohistochemical staining of sections of human aorta using an antibody directed against
HOXA4 showed expression in all three histological layers of the aorta, primarily by endothelial
cells and smooth muscle cells. Immunohistochemical analysis and immunofluorescent staining
of cultured cells in vitro demonstrated protein expression localizing to the nucleus and
perinuclear regions of endothelial and smooth muscle cells. Quantitative analysis of HOXA4
protein by western blot in 24 paired human thoracic and abdominal aortic samples showed that,
consistent with the microarray results, HOXA4 had significantly lower expression (p < 0.0001) in
the abdominal aorta. A negative correlation was also shown between HOXA4 was
demonstrated between HOXA4 protein levels and increasing in both thoracic and abdominal
aorta.
In conclusion, several novel genes with potential roles in AAA etiology and pathogenesis
have been identified using two different methods. Two plausible functional candidate genes
from a region with evidence of genetic linkage, CD22 and PEPD, were shown to have evidence
of nominal association, suggesting that variation in or around these genes may contribute to the
risk of developing an AAA. HOXA4 is a novel candidate gene with differential expression by
aortic location and age. Lower levels of HOXA4 in the abdominal aorta and further decreases in
expression with increasing age suggest that HOXA4 may have a protective function with respect
to AAA.
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